US7759379B2 - Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors - Google Patents
Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors Download PDFInfo
- Publication number
- US7759379B2 US7759379B2 US11/627,518 US62751807A US7759379B2 US 7759379 B2 US7759379 B2 US 7759379B2 US 62751807 A US62751807 A US 62751807A US 7759379 B2 US7759379 B2 US 7759379B2
- Authority
- US
- United States
- Prior art keywords
- different
- chosen
- optionally substituted
- alkyl
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 0 *C1([4*])CC(=O)N(*([3*])CCN([1*])[2*])C(=O)N1C[Y][5*] Chemical compound *C1([4*])CC(=O)N(*([3*])CCN([1*])[2*])C(=O)N1C[Y][5*] 0.000 description 29
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- the present invention relates to novel amino cyclic urea derivatives, to a process for preparing them, to their use as medicinal products, to pharmaceutical compositions containing them and to the pharmaceutical use of such derivatives for preventing and treating complaints that may be modulated by inhibiting the activity of protein kinases.
- the present invention relates to novel amino cyclic urea derivatives that have inhibitory effects on protein kinases.
- the products of the present invention may thus be used especially for preventing or treating complaints capable of being modulated by inhibiting the activity of protein kinases.
- the inhibition and regulation of protein kinases especially constitute a powerful new mechanism of action for treating a large number of solid tumours.
- Such protein kinases belong especially to the following group:
- Such protein kinases belong more especially to the following group: IGF1, cdc7, Auroral-2, Src, Jnk, FAK, KDR, IR, Tie2, CDK7, CDK2 et EGFR.
- the protein kinase IGF1-R (Insulin Growth Factor-1 Receptor) is particularly indicated.
- the protein kinase FAK is also indicated.
- the protein kinase AKT is also indicated.
- the present invention thus relates particularly to novel inhibitors of the IGF-1R receptor that may be used for oncology treatments.
- the present invention also relates to novel FAK receptor inhibitors that may be used for oncology treatments.
- the present invention also relates to novel AKT receptor inhibitors that may be used for oncology treatments.
- Cancer remains a disease for which the existing treatments are clearly insufficient.
- Certain protein kinases especially including IGF-1R (Insulin Growth Factor 1 Receptor), play an important role in many cancers.
- the inhibition of such protein kinases is potentially important in the chemotherapy of cancers, especially for suppressing the growth or survival of tumours.
- the present invention thus relates to the identification of novel products that inhibit such protein kinases.
- Protein kinases participate in signalling events that control the activation, growth and differentiation of cells in response either to extracellular mediators or to changes in the environment. In general, these kinases belong to two groups: those that preferentially phosphorylate serine and/or threonine residues and those that preferentially phosphorylate tyrosine residues [S. K. Hanks and T. Hunter, FASEB. J., 1995, 9, pages 576-596].
- the serine/threonine kinases are, for example, the isoforms of the protein kinases C [A. C. Newton, J. Biol.
- Tyrosine kinases comprise growth factor receptors, for instance the epidermal growth factor (EGF) receptor [S. Iwashita and M. Kobayashi, Cellular Signalling, 1992, 4, pages 123-132], and cytosol kinases, for instance p56tck, p59fYn and ZAP-70 and the kinases csk [C. Chan et. al., Ann. Rev. Immunol., 1994, 12, pages 555-592].
- EGF epidermal growth factor
- kinase protein activity has been implicated in many diseases, resulting from abnormal cellular functions. This may arise either directly or indirectly from a dysfunction in the mechanisms for controlling the kinase activity, linked, for example, to a mutation, an overexpression or an inappropriate activation of the enzyme, or an over or underproduction of cytokines or of growth factors, also involved in the transduction of the signals upstream or downstream of the kinases. In all these cases, a selective inhibition of the action of the kinases offers hope of a beneficial effect.
- the type 1 receptor for the insulin-like growth factor is a transmembrane receptor with tyrosine kinase activity which binds firstly to IGFI, but also to IGFII and to insulin with lower affinity.
- the binding of IGF1 to its receptor results in oligomerization of the receptor, the activation of tyrosine kinase, intermolecular autophosphorylation and the phosphorylation of cell substrates (main substrates: IRS1 and Shc).
- the receptor activated by its ligand induces mitogenic activity in normal cells.
- IGF-I-R plays an important role in “abnormal” growth.
- IGF-I-R is often found overexpressed in many types of tumour (breast, colon, lung, sarcoma, etc.) and its presence is often associated with a more aggressive phenotype.
- High concentrations of circulating IGF1 are strongly correlated with a risk of prostate cancer, lung cancer and breast cancer.
- IGF-I-R is necessary for establishing and maintaining the transformed phenotype in vitro as in vivo [Baserga R, Exp. Cell. Res., 1999, 253, pages 1-6].
- the kinase activity of IGF-I-R is essential for the transformation activity of several oncogenes: EGFR, PDGFR, the large T antigen of the SV40 virus, activated Ras, Raf, and v-Src.
- the expression of IGF-I-R in normal fibroblasts induces a neoplastic phenotype, which may then result in the formation of a tumour in vivo.
- the expression of IGF-I-R plays an important role in substrate-independent growth.
- IGF-I-R has also been shown to be a protector in chemotherapy-induced and radiation-induced apoptosis, and cytokine-induced apoptosis. Furthermore, the inhibition of endogenous IGF-I-R with a negative dominant, the formation of a triple helix or the expression of an antisense sequence brings about suppression of the transforming activity in vitro and reduction of tumour growth in animal models.
- FAK Fluorescence Adhesion Kinase
- FAK is a cytoplasmic tyrosine kinase that plays an important role in transducing the signal transmitted by the integrins, a family of heterodimeric receptors of cellular adhesion.
- FAK and the integrins are colocalized in perimembrane structures known as adhesion plaques. It has been shown in many cell types that the activation of FAK and its phosphorylation on tyrosine residues and in particular its autophosphorylation on tyrosine 397 were dependent on the binding of the integrins to their extracellular ligands and thus induced during cellular adhesion [Kornberg L, et al. J. Biol. Chem. 267(33): 23439-442 (1992)].
- the autophosphorylation on tyrosine 397 of FAK represents a binding site for another tyrosine kinase, Src, via its SH2 domain [Schaller et al. Mol. Cell. Biol. 14: 1680-1688 1994; Xing et al. Mol. Cell. Biol. 5: 413-421 1994].
- Src can then phosphorylate FAK on tyrosine 925, thus recruiting the adapter protein Grb2 and inducing in certain cells activation of the ras and MAP kinase pathway involved in controlling cellular proliferation [Schlaepfer et al. Nature; 372: 786-791 1994; Schlaepfer et al. Prog. Biophy. Mol. Biol. 71: 435-478 1999; Schlaepfer and Hunter, J. Biol. Chem. 272: 13189-13195 1997].
- PI3-kinase Phosphatidylinositol-3-OH kinase
- the FAK/Src complex phosphorylates various substrates, for instance paxillin and p130CAS in fibroblasts [Vuori et al. Mol. Cell. Biol. 16: 2606-2613 1996].
- fibroblasts that are deficient for the expression of FAK (“knockout” mice for FAK) show a rounded morphology and deficiencies in cell migration in response to chemotactic signals, and these defects are suppressed by reexpression of FAK [D J. Sieg et al., J. Cell Science. 112: 2677-91 1999].
- the overexpression of FAK in CHO or COS cells or in human astrocytoma cells promotes migration of the cells.
- Protein kinase AKT also known as PKB
- PI3K phosphoinositide 3-kinase
- AKT serine/threonine kinase
- hypoxia modulates the induction of VEGF in cells transformed with Ha-ras by activating the PI3K/AKT pathway and by involving the binding sequence of the HIF-1 (hypoxia inducible factor-1) transcription factor known as HRE for “hypoxy-responsive element”.
- AKT plays a very important role in cancer pathologies.
- the amplification and/or overexpression of AKT has been reported in many human tumours, for instance gastric carcinoma (amplification of AKT1), ovary carcinomas, breast carcinoma or pancreatic carcinoma (amplification and overexpression of AKT2) and breast carcinomas deficient in oestrogen receptors, and also androgen-independent prostate carcinomas (overexpression of AKT3).
- AKT is constitutively activated in all the PTEN tumours, the PTEN phosphatase being deleted or inactivated by mutations in many types of tumours, for instance carcinomas of the ovary, of the prostate, of the endometrium, glioblastomas and melanomas.
- AKT is also involved in the oncogenic activation of bcr-abl (references: Khawaja A., Nature 1999, 401, 33-34; Cardone et al. Nature 1998, 282, 1318-1321; Kitada S. et al., Am J Pathol 1998 Jan; 152(1): 51-61; Mazure N M et al. Blood 1997, 90, 3322-3331; Zhong H. et al. Cancer Res. 2000, 60, 1541-1545).
- p represents the integers 0, 1 and 2
- A represents aryl, heteroaryl or a monocyclic or bicyclic fused carbocyclic or heterocyclic 5- to 11-membered radical, all these radicals optionally being substituted with one or more substituents, which may be identical or different, chosen from the values of R3;
- X represents a single bond or the following divalent radicals: —N(R6)-; —NH-alk-; alkylene; —O—; —C(O)—; —S(O)n-; —N(R6)-C(O)—; —NH—CO-alk-, —N(R6)-C(O)—N(R6′)-; —N(R6)-C(S)—N(R6′)-; —N(R6)-C(O)O—; —N(R6)-SO2-; —N(R6)-SO2-N(R6′)-; —C(O)—N(R6)-; —SO2-NR6-; and —C(O)O—;
- L1 represents a single bond or the following divalent radicals: alkylene, alkenylene, alkynylene and cycloalkylene, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; phenylene and heteroarylene, these last two radicals optionally substituted with one or more substituents chosen from the values of R8;
- the radical NR1R2 is such that:
- R1 and R2 which may be identical or different, are such that:
- R1 represents a hydrogen atom; alkyl, alkenyl, alkynyl and cycloalkyl, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; aryl, heteroaryl, arylalkyl and heteroarylalkyl in which each of the aromatic rings may optionally be substituted with one or more substituents, which may be identical or different, chosen from the values of R8; —SO2R9; —C(O)R9; —C(O)OR9; —C(O)NR10R11, —C(S)NR10R11 and —SO2NR10R11;
- R2 represents a hydrogen atom; alkyl, alkenyl, alkynyl and cycloalkyl, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R1 and R2 form, together with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, NR12 and S, and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- NR1 with L1 or NR2 with L 1 together form a 4- to 10-membered heterocycle—optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, NR12 and S, and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R3 represents a hydrogen atom; a halogen atom; hydroxyl; alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy and alkylenedioxy, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; —NR13R14; —C(O)R13; —S(O) n R13; —C(O)OR13; —C(O)NR15R16; —S(O) n NR15R16; SF5; nitro; cyano; 4- to 7-membered heterocycloalkyl optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and alkyl, alkoxy or oxo radicals; aryl and heteroaryl, these last two radicals optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8; being noted that when A
- R4 represents a hydrogen atom; a halogen atom; an alkyl, alkenyl, alkynyl or cycloalkyl radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; aryl and heteroaryl, these last two radicals optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8; oxo; it being understood that two substituents from among R4, R4′ and R4′′ may form, with the carbon atom(s) to which they are attached, a 3- to 10-membered ring optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12;
- L2 is chosen from a single bond; an alkylene; alkenylene; alkynylene; cycloalkylene; —O—; —NR17-; —C(O)— and SO2 radical;
- Y represents a saturated, partially saturated or unsaturated N-heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R5;
- R5 represents a hydrogen atom; a halogen atom; an alkyl, alkenyl, alkynyl or cycloalkyl radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; aryl, arylalkyl, heteroaryl and heteroarylalkyl, in which the aromatic rings are optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8; —OR18; —NR19R20; —NR19COR20; —NR19CONR19′R20; —NR19-S(O)2-R20; —NR19-S(O)2-NR19′R20; —COR18; COOR21; —CONR22R23; —S(O)nR18; —SO2NR22R23; cyano; nitro;
- R6 is such that:
- R6 represents a hydrogen atom; an alkyl, alkenyl, alkynyl, acyl or cycloalkyl radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; aryl and heteroaryl, these last two radicals optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8;
- R6 with NR1R2 together form a 4- to 8-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R6 with L1 together form a 4- to 8-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R6′ which may be identical to or different from R6, is chosen from the values of R6;
- R7 represents a halogen atom; alkyl; cycloalkyl; cycloalkylalkyl; hydroxyl; alkoxy; cycloalkoxy; cyano; —CF3; —NR24R25; —NR26COR27; —NR26CONR26′R27; —NR26-S(O)2-R27; —NR26-S(O)2-NR26′R27; —COOR26; —COR26; —CO(NR24R25); S(O)nR26; —S(O)2NR24R25; 4- to 7-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from OH and NH2 radicals, halogen atoms, and alkyl, alkoxy or oxo radicals; aryl optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkyl and alkoxy radicals
- R8 which may be identical to or different from R7, represents the same values as R7 and in addition represents halogen atoms; nitro; —OCF3; alkylenedioxy; difluoromethylenedioxy; benzyl optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkyl and alkoxy radicals;
- R9 which may be identical to or different from R6, represents the same values as R6;
- R10 and R11 which may be identical to or different from each other and also which may be identical to or different from R6, are chosen from the same values as R6 and may optionally form, with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R12 represents a hydrogen atom; an alkyl, alkenyl, alkynyl, cycloalkyl, alkylCO or alkylSO 2 radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms, OH, alkoxy and dialkylamino radicals; aryl and heteroaryl, these last two radicals optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkyl and alkoxy radicals;
- R13 which may be identical to or different from R6, represents the same values as R6;
- R14 which may be identical to or different from R13, represents the same values as R13 and also represents C(O)R28; C(O)N28R29; SO2R28 and SO2NR28R29;
- R13 and R14 may optionally form, together with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R15 and R16 which may be identical to or different from each other and also which may be identical to or different from R13, are chosen from the same values as R13 and may optionally form, with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R17 represents a hydrogen atom, alkyl or cycloalkyl
- R18 which may be identical to or different from R6, represents the same values as R6;
- R19 and R20 which may be identical to or different from each other and also which may be identical to or different from R6, are chosen from the same values as R6 and may optionally form, with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R21 which may be identical to or different from R13, represents the same values as R13 and also represents hydrogen;
- R22 and R23 which may be identical to or different from each other and also which may be identical to or different from R6, are chosen from the same values as R6 and may optionally form, with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R24 and R25 which may be identical or different, represent a hydrogen atom or an alkyl, alkenyl or alkynyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and OH and alkoxy radicals, or alternatively R24 and R25 may optionally form, with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, N-alkyl and N-C(O)alkyl, and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and OH, alkyl, alkoxy and oxo radicals;
- R26 represents a hydrogen atom or an alkyl, alkenyl or alkynyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and OH and alkoxy radicals;
- R27 which may be identical to or different from R26, represents the same values as R26;
- R26 and R27 may also optionally form, with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, N-alkyl and N-C(O)alkyl, and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and OH, alkyl, alkoxy and oxo radicals;
- R28 which may be identical to or different from R26, represents the same values as R26;
- R29 which may be identical to or different from R26, represents the same values as R26;
- R30 which may be identical to or different from R26, represents the same values as R26;
- n the integers 0, 1 and 2;
- the said products of formula (I) being in any possible racemic, enantiomeric and diastereoisomeric isomer form, and also the addition salts with mineral acids and organic acids or with mineral bases and organic bases of the said products of formula (I).
- p represents the integers 0, 1 and 2
- A represents aryl, heteroaryl or a monocyclic or bicyclic fused carbocyclic or heterocyclic 5- to 11-membered radical, all these radicals optionally being substituted with one or more substituents, which may be identical or different, chosen from the values of R3;
- X represents a single bond or the following divalent radicals: —N(R6)-; —O—; —C(O)—; —S(O)n-; —N(R6)-C(O)—; —N(R6)-C(O)—N(R6′)-; —N(R6)-C(S)—N(R6′)-; —N(R6)-C(O)O—; —N(R6)-SO2-; —N(R6)-SO2-N(R6′)-; —C(O)—N(R6)-; —SO2-NR6-; and —C(O)O—;
- L1 represents the following divalent radicals: alkylene, alkenylene, alkynylene and cycloalkylene, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; phenylene and heteroarylene, these last two radicals optionally substituted with one or more substituents chosen from the values of R8;
- the radical NR1R2 is such that
- R1 and R2 which may be identical or different, are such that:
- R1 represents a hydrogen atom; alkyl, alkenyl, alkynyl and cycloalkyl, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; aryl, heteroaryl, arylalkyl and heteroarylalkyl in which each of the aromatic rings may optionally be substituted with one or more substituents, which may be identical or different, chosen from the values of R8; —SO2R9; —C(O)R9; —C(O)OR9; —C(O)NR10R11, —C(S)NR10R11 and —SO2NR10R11;
- R2 represents a hydrogen atom; alkyl, alkenyl, alkynyl and cycloalkyl, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R1 and R2 form, together with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, NR12 and S, and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- NR1 with L1 or NR2 with L 1 together form a 4- to 8-membered heterocycle optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, NR12 and S, and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R3 represents a hydrogen atom; a halogen atom; hydroxyl; alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy and alkylenedioxy, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; —NR13R14; —C(O)R13; —S(O) n R13; —C(O)OR13; —C(O)NR15R16; —S(O) n NR15R16; SF5; nitro; cyano; 4- to 7-membered heterocycloalkyl optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and alkyl, alkoxy or oxo radicals; aryl and heteroaryl, these last two radicals optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8; being noted that when A
- R4 represents a hydrogen atom; a halogen atom; an alkyl, alkenyl, alkynyl or cycloalkyl radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; aryl and heteroaryl, these last two radicals optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8; oxo; it being understood that two substituents from among R4, R4′ and R4′′ may form, with the carbon atom(s) to which they are attached, a 3- to 10-membered ring optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12;
- L2 is chosen from a single bond; an alkylene; alkenylene; alkynylene; cycloalkylene; —O—; —NR17-; —C(O)— and SO2 radical;
- Y represents a saturated, partially saturated or unsaturated N-heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R5;
- R5 represents a hydrogen atom; a halogen atom; an alkyl, alkenyl, alkynyl or cycloalkyl radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; aryl, arylalkyl, heteroaryl and heteroarylalkyl, in which the aromatic rings are optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8; —OR18; —NR19R20; —NR19COR20; —NR19CONR19′R20; —NR19-S(O)2-R20; —NR19-S(O)2-NR19′R20; —COR18; COOR21; —CONR22R23; —S(O)nR18; —SO2NR22R23; cyano; nitro;
- R6 is such that:
- R6 represents a hydrogen atom; an alkyl, alkenyl, alkynyl or cycloalkyl radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; aryl and heteroaryl, these last two radicals optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8;
- R6 with NR1R2 together form a 4- to 8-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R6 with L1 together form a 4- to 8-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R6′ which may be identical to or different from R6, is chosen from the values of R6;
- R7 represents a halogen atom; alkyl; cycloalkyle; cycloalkylalkyle; hydroxyl; alkoxy; cycloalkoxy; cyano; —CF3; —N24R25; —NR26COR27; —NR26CONR26′R27; —NR26-S(O)2-R27; —NR26-S(O)2-NR26′R27; —COOR26; —COR26; —CO(NR24R25); S(O)nR26; —S(O)2NR24R25; 4- to 7-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from OH and NH2 radicals, halogen atoms, and alkyl, alkoxy or oxo radicals; aryl optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkyl and alkoxy radicals
- R8 which may be identical to or different from R7, represents the same values as R7 and in addition represents halogen atoms; nitro; —OCF3; alkylenedioxy; difluoromethylenedioxy; benzyl optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkyl and alkoxy radicals;
- R9 which may be identical to or different from R6, represents the same values as R6;
- R10 and R11 which may be identical to or different from each other and also which may be identical to or different from R6, are chosen from the same values as R6 and may optionally form, with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R12 represents a hydrogen atom; an alkyl, alkenyl, alkynyl, cycloalkyl, alkylCO or alkylSO 2 radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms, OH, alkoxy and dialkylamino radicals; aryl and heteroaryl, these last two radicals optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkyl and alkoxy radicals;
- R13 which may be identical to or different from R6, represents the same values as R6;
- R14 which may be identical to or different from R13, represents the same values as R13 and also represents C(O)R28; C(O)N28R29; SO2R28 and SO2NR28R29;
- R13 and R14 may optionally form, together with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R15 and R16 which may be identical to or different from each other and also which may be identical to or different from R13, are chosen from the same values as R13 and may optionally form, with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R17 represents a hydrogen atom, alkyl or cycloalkyl
- R18 which may be identical to or different from R6, represents the same values as R6;
- R19 and R20 which may be identical to or different from each other and also which may be identical to or different from R6, are chosen from the same values as R6 and may optionally form, with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R21 which may be identical to or different from R13, represents the same values as R13 and also represents hydrogen;
- R22 and R23 which may be identical to or different from each other and also which may be identical to or different from R6, are chosen from the same values as R6 and may optionally form, with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12 and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R24 and R25 which may be identical or different, represent an alkyl, alkenyl or alkynyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and OH and alkoxy radicals, or alternatively R24 and R25 may optionally form, with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, N-alkyl and N-C(O)alkyl, and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and OH, alkyl, alkoxy and oxo radicals;
- R26 represents a hydrogen atom or an alkyl, alkenyl or alkynyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and OH and alkoxy radicals;
- R27 which may be identical to or different from R26, represents the same values as R26;
- R26 and R27 may also optionally form, with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, N-alkyl and N-C(O)alkyl, and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and OH, alkyl, alkoxy and oxo radicals;
- R28 which may be identical to or different from R26, represents the same values as R26;
- R29 which may be identical to or different from R26, represents the same values as R26;
- R30 which may be identical to or different from R26, represents the same values as R26;
- n the integers 0, 1 and 2;
- the said products of formula (I) being in any possible racemic, enantiomeric and diastereoisomeric isomer form, and also the addition salts with mineral acids and organic acids or with mineral bases and organic bases of the said products of formula (I).
- alkyl radicals containing not more than 6 carbon atoms and especially methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, linear or branched pentyl and linear or branched hexyl radicals.
- alkenyl values that may be mentioned more particularly are the values allyl or butenyl.
- alkynyl values that are mentioned more particularly is the propargyl value.
- Heterocycloalkyl radicals that may especially be mentioned include dioxolane, dioxane, dithiolane, thiooxolane, thiooxane, oxiranyl, oxolanyl, dioxolanyl, piperazinyl, piperidyl, pyrrolidyl, imidazolidinyl, pyrazolidinyl, morpholinyl, or tetrahydrofuryl, tetrahydrothienyl, chromanyl, dihydrobenzofuranyl, indolinyl, piperidyl, perhydropyranyl, pyrindolinyl, tetrahydroquinolyl, tetrahydroisoquinolyl and thioazolidinyl radicals, all these radicals being optionally substituted.
- heterocycloalkyl radicals that may especially be mentioned are optionally substituted piperazinyl, optionally substituted piperidyl, optionally substituted pyrrolidinyl, imidazolidinyl, pyrazolidinyl, morpholinyl and thioazolidinyl radicals: mention may also be made more particularly of optionally substituted morpholinyl, pyrrolidyl and piperazinyl radicals;
- 6-membered heteroaryl radicals such as 2-pyridyl, 3-pyridyl and 4-pyridyl, and pyrimidyl, pyrimidinyl, pyridazinyl, pyrazinyl and tetrazolyl radicals;
- fused heteroaryl radicals that may be mentioned more particularly are benzothienyl, benzofuranyl, indolyl, quinolyl, benzimidazolyl, benzothiazolyl, furyl, imidazolyl, indolizinyl, isoxazolyl, isoquinolyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, 1,3,4-thiadiazolyl, thiazolyl and thienyl radicals and triazolyl groups, these radicals optionally being substituted as indicated for the heteroaryl radicals;
- patient denotes human beings, but also other mammals.
- prodrug denotes a product that may be converted in vivo via metabolic mechanisms (such as hydrolysis) into a product of formula (I).
- metabolic mechanisms such as hydrolysis
- an ester of a product of formula (I) containing a hydroxyl group may be converted by hydrolysis in vivo into its parent molecule.
- an ester of a product of formula (I) containing a carboxyl group may be converted by in vivo hydrolysis into its parent molecule.
- esters of the products of formula (I) containing a hydroxyl group include the acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylenebis- ⁇ -hydroxynaphthoates, gentisates, isethionates, di-p-tolyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.
- Esters of products of formula (I) that are particularly useful, containing a hydroxyl group may be prepared from acid residues such as those described by Bundgaard et. al., J. Med. Chem., 1989, 32, page 2503-2507: these esters especially include substituted (aminomethyl)benzoates, dialkylaminomethylbenzoates in which the two alkyl groups may be linked together or may be interrupted with an oxygen atom or with an optionally substituted nitrogen atom, i.e. an alkylated nitrogen atom, or alternatively (morpholinomethyl)benzoates, e.g. 3- or 4-(morpholinomethyl)benzoates, and (4-alkylpiperazin-1-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-1-yl)benzoates.
- substituted (aminomethyl)benzoates dialkylaminomethylbenzoates in which the two alkyl groups may be linked together or may be interrupted with an oxygen atom
- the carboxyl radical(s) of the products of formula (I) may be salified or esterified with various groups known to those skilled in the art, among which nonlimiting examples that may be mentioned include the following compounds:
- esterified carboxyl means, for example, radicals such as alkyloxycarbonyl radicals, for example methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butyl or tert-butyloxycarbonyl, cyclobutyloxycarbonyl, cyclopentyloxycarbonyl or cyclohexyloxycarbonyl.
- radicals formed with readily cleavable ester residues such as methoxymethyl or ethoxymethyl radicals; acyloxyalkyl radicals such as pivaloyloxymethyl, pivaloyloxyethyl, acetoxymethyl or acetoxyethyl; alkyloxycarbonyloxyalkyl radicals such as methoxycarbonyloxy methyl or ethyl radicals, and isopropyloxycarbonyloxy methyl or ethyl radicals.
- ester radicals may be found, for example, in European patent EP 0 034 536.
- aminoated carboxyl means radicals of the type —CONRxRy in which the amino radicals —NRxRy have the meanings given above: especially, Rx and Ry, which may be identical or different, represent a hydrogen atom, a cyclic radical as defined above or below or an alkyl radical containing from 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl radicals and especially amino, alkylamino and dialkylamino radicals, all these cyclic and alkyl radicals being optionally substituted.
- alkylamino radical means, for example, linear or branched methylamino, ethylamino, propylamino or butylamino radicals. Alkyl radicals containing not more than 4 carbon atoms are preferred, the alkyl radicals possibly being chosen from the alkyl radicals mentioned above.
- dialkylamino radical means, for example, dimethylamino, diethylamino and methylethylamino radicals. As previously, alkyl radicals containing not more than 4 carbon atoms, chosen from the list indicated above, are preferred.
- salts formed for example, with one equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium. Mention may also be made of the salts formed with organic bases such as methylamine, propylamine, trimethylamine, diethylamine and triethylamine. The sodium salt is preferred.
- the addition salts with mineral or organic acids of the products of formula (I) may be, for example, the salts formed with hydrochloric acid, hydrobromic acid, hydriodic acid, nitric acid, sulphuric acid, phosphoric acid, propionic acid, acetic acid, trifluoroacetic acid, formic acid, benzoic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, oxalic acid, glyoxylic acid, aspartic acid, ascorbic acid, alkylmonosulphonic acids such as, for example, methanesulphonic acid, ethanesulphonic acid or propanesulphonic acid, alkyldisulphonic acids such as, for example, methanedisulphonic acid or ⁇ , ⁇ -ethanedisulphonic acid, arylmonosulphonic acids such as benzenesulphonic acid, and aryldisulphonic acids.
- hydrochloric acid hydrobromic acid
- stereoisomerism may be defined in its broad sense as the isomerism of compounds having the same structural formulae but whose various groups are arranged differently in space, especially such as in monosubstituted cyclohexanes whose substituent may be in an axial or equatorial position, and the various possible rotational conformations of ethane derivatives.
- stereoisomerism due to the different spatial arrangements of fixed substituents, either on double bonds or on rings, which is often referred to as geometrical isomerism or cis-trans isomerism.
- the term “stereoisomer” is used in the present patent application in its broadest sense and thus relates to all the compounds indicated above.
- a subject of the present invention is thus the products of general formula (I) as defined above in which
- A represents a phenyl or heteroaryl radical or a monocyclic or bicyclic fused carbocyclic or heterocyclic 5- to 11-membered radical, optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R3,
- X represents a single bond or the following divalent radicals: —N(R6)-, —O—, —C(O)—, —S(O)n-, —N(R6)-C(O)—, —N(R6)-C(O)—N(R6′)-, —N(R6)-SO2-, —C(O)—N(R6)- and —SO2 NR6;
- R6 and R6′ which may be identical or different, and the other substituents of the said products of formula (I) being chosen from all the values defined for R6 and R6′ and for the said substituents,
- X more particularly represents a single bond or the following divalent radicals: —N(R6)-, —O—, —C(O)— —S(O)n-, —N(R6)-C(O)— and —N(R6)-SO2-;
- X most particularly represents a single bond or the following divalent radicals: —N(R6)-, —O—, —C(O)—, and —NH—C(O)—;
- L1 represents an alkylene radical containing 1 to 4 carbon atoms and optionally substituted with one or several substituents chosen from the values of R7, with R7 and the other substituents of the said products of formula (I) being chosen from all the values defined for R7 and for the substituents,
- L1 more particularly represents an alkylene radical containing 1 to 4 carbon atoms and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms (F), and OH and alkoxy radicals;
- L1 represents even more particularly particularly an alkylene radical containing 1 to 4 carbon atoms optionally substituted with a hydroxyl radical
- L1 most particularly represents an alkylene radical containing 1 to 4 carbon atoms
- radical NR1R2 is such that:
- R1 and R2 which may be identical or different, are such that:
- R1 represents a hydrogen atom, an alkyl or cycloalkyl radical, these last two radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; aryl, heteroaryl, arylalkyl, heteroarylalkyl in which each of the aromatic rings may be optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8;
- R2 represents a hydrogen atom, an alkyl or cycloalkyl radical, these last two radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R1 and R2 form, together with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more other heteroatoms, which may be identical or different, chosen from O, N, NR12 and S and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- NR1 with L1 or NR2 with L 1 together form a 4- to 8-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R7, R8, R12 and L1 and the other substituents of the said products of formula (I) being chosen from all the values defined for R7, R8, R12 and L1 and for the said substituents,
- NR1R2 is particularly defined as follows:
- R1 and R2 which may be identical or different, are such that:
- R1 represents a hydrogen atom, an alkyl or cycloalkyl radical, these last two radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; aryl and heteroaryl, both optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8;
- R2 represents a hydrogen atom, an alkyl or cycloalkyl radical, these last two radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- R1 and R2 form, together with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, N-alkyl and S and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- NR1 with L1 or NR2 with L 1 together form a 4- to 8-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7;
- radical NR1R2 is more particularly defined as follows:
- R1 and R2 which may be identical or different, are such that:
- R1 represents an alkyl or cycloalkyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms (F) and hydroxyl; alkoxy; cyano, free or esterified carboxyl, phenyl, 3- to 7-membered cycloalkyl, alkylamino, dialkylamino, —NHCO-alkyl, —CO(NH-alkyl), CO(Ndialkyl) radicals and 5-, 6- or 7-membered saturated, partially saturated or unsaturated heterocyclyl radicals containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, NH or N-alkyl and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkyl, NH2 and alkoxy radicals; or alternatively R1 represents a phenyl radical or a saturated, partially saturated or unsaturated 4- to 7-
- R2 represents a hydrogen atom, an alkyl or cycloalkyl radical optionally substituted with one or more halogen atoms;
- R1 and R2 form, together with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, NH, N-alkyl and S and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms, alkyl, alkoxy, CF3 and free or esterified carboxyl radicals;
- NR1R2 and L 1 together form a 4- to 7-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms, alkyl and alkoxy and free or esterified carboxyl radicals;
- radical NR1R2 is even more particularly defined as follows:
- R1 and R2 which may be identical or different, are such that:
- R1 represents an alkyl radical optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkoxy, cyano, free or esterified carboxyl, phenyl and 3- to 7-membered cycloalkyl radicals, and saturated, partially saturated or unsaturated 4- to 7-membered heterocyclic radical, itself containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, NH and N-alkyl and optionally substituted with one or more alkyl radicals, and
- R1 represents a 3- to 7-membered cycloalkyl radical, a phenyl radical or a saturated, partially saturated or unsaturated 4- to 7-membered heterocyclic radical, itself containing one or more hetero atoms chosen from O, S, N, NH and N-alkyl, and optionally substituted with one or more alkyl radicals
- R2 represents a hydrogen atom or an alkyl radical optionally substituted with one or more halogen atoms
- R1 and R2 form, with the nitrogen atom to which they are attached, a saturated or unsaturated 4- to 7-membered heterocyclic radical optionally containing one or more other hetero atoms chosen from O, S, N, NH and N-alkyl, this radical formed by R1 and R2 with N being itself optionally substituted with one or more radicals, which may be identical or different, chosen from alkyl, CF3 and free or esterified carboxyl radicals,
- NR1 with L1 or NR2 and L1 together form a saturated or unsaturated 4- to 7-membered heterocycle containing at least one nitrogen atom and optionally containing one or more other hetero atoms chosen from O, S, N, NH and N-alkyl, this radical formed by NR1R2 with L1d itself being optionally substituted with one or more radicals chosen from alkyl and free or esterified carboxyl radicals,
- R7, R8 and L1 and the other substituents of the said products of the formula (I) being chosen from all the values defined for R7, R8 and L1 and for the said substituents, the said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said products of formula (I).
- R3 represents a hydrogen atom, a halogen atom; an alkyl, cycloalkyl, alkoxy or alkylenedioxy radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; —NR13R14; —C(O)R13; —S(O) n R13; —C(O)NR15R16; —S(O) n NR15R16; aryl and heteroaryl, these last two radicals optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8;
- R7, R8, R13, R14, R15 and R16 and the other substituents of the said products of formula (I) being chosen from all the values defined for R7, R8, R13, R14, R15 and R16 and for the said substituents,
- R3 more particularly represents a hydrogen atom; alkyl, alkoxy and cycloalkyl radicals optionally substituted with one or more halogen atoms; OCF3 and S(O) n -alkyl radicals, the alkyl residue containing 1 to 4 carbon atoms and being optionally substituted with one or more halogen atoms; alkylamino, optionally substituted with one or more halogen atoms; dialkylamino, in which the two alkyl residues may optionally form with the nitrogen atom to which they are attached a 4- to 10-membered heterocyclic radical optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, N-alkyl and S and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms (F) and alkyl and alkoxy radicals;
- R3 particularly represents one or more substituents of the ring A, which may be identical or different, chosen from alkyl, alkoxy, cycloalkyl, alkylamino and dialkylamino, each optionally substituted with one or more halogen atoms and in which alkyl and alcoxy contain up to 4 carbon atoms; OCF3; SCF3; and SO2CF3;
- R3 especially represents one or more substituents of the ring A, which may be identical or different, chosen from a hydrogen atom and alkyl, OCH3, SCF3 and —OCF3 radicals; the ring A and the other substituents of the said products of formula (I) being chosen from all the values defined for the ring A and for the said substituents,
- a subject of the present invention is thus the products of general formula (I) as defined above, in which
- R4 represents a hydrogen atom, a halogen atom (F), an alkyl or cycloalkyl radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7; it being understood that two substituents R4 may form, with the carbon atom(s) to which they are attached, a 3- to 7-membered ring optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and N-alkyl;
- R4 more particularly represents a hydrogen atom, a halogen atom and an alkyl or cycloalkyl radical optionally substituted with one or more halogen atoms; it being understood that two substituents R4 may form, with the carbon atom to which they are attached, a 3- to 5-membered carbo or heterocyclic spirocyclic ring;
- R4 even more particularly represents hydrogen, alkyl or spiro cycloalkyl; the other substituents of the said products of formula (I) being chosen from all the values defined for the said substituents,
- R4 may especially represent hydrogen and alkyl, it being understood that two substituents R4 borne by the same carbon, can form, together with the carbon atom to which they are attached, a 3- to 6-membered cycloalkyl or heterocycloalkyl radical containing a nitrogen atom;
- R4 represents hydrogen and CH3, it being understood that two substituents R4, borne by the same carbon, can form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms or an azetidinyl, pyrrolidinyl or piperidyl radical.
- the ring formed is especially a cycloalkyl radical containing from 3 to 6 carbon atoms, and more particularly a cyclopropyl radical;
- L2 is chosen from a single bond and an alkylene, cycloalkylene, —O— or —NR17— radical,
- L2 especially represents cycloalkylene, —O— and —NR17—; L2 more particularly represents a single bond and methylene;
- L2 even more particularly represents —CH2
- a subject of the present invention is thus the products of general formula (I) as defined above in which
- Y represents an N-heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S and N and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R5;
- Y especially represents a monocyclic or bicyclic heteroaryl radical chosen from pyridyl, pyrimidinyl, pyridazine, pyrazine, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, isoxazolyl, 1H-pyrrolo[2,3-b]pyridyl, furazanyl, morpholinyl, pyrrolidinyl, indazolyl, 3H-imidazo-(4,5b)-pyridine, 1H-pyrazolo-(3,4b)-pyridine, 1H-pyrazolo-(3,4d)-pyrimidine, piperidyl, thienyl, indolyl, pyrrolyl, purinyl, benzoxazinyl, benzimidazolyl, these radical
- Y particularly represents a heteroaryl radical chosen from pyridyl, pyrimidinyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, thiazolyl, imidazolyl, oxazolyl, pyrazolyl and isoxazolyl, these radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R5;
- Y more particularly represents a heteroaryl radical chosen from pyridyl, pyrimidinyl, quinolyl, isoquinolyl; azaindolyl, quinazolinyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl and isoxazolyl radicals,
- radicals being optionally substituted with one or more radicals chosen from the values of R5;
- Y even more particularly represents a heteroaryl radical chosen from pyrid-4-yl, pyrid-3-yl, pyrimidin-4-yl, quinolin-4-yl, quinolin-3-yl, isoquinolin-5-yl, azaindol-4-yl and quinazolin-4-yl, these radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R5;
- Y most particularly represents a heteroaryl radical chosen from pyrid-4-yl, pyrimidin-4-yl, quinolin-4-yl, isoquinolin-5-yl, azaindol-4-yl and quinazolin-4-yl, these radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R5;
- Y more specifically represents 4-pyridyl and 4-quinolyl radicals, optionally substituted with one or more radicals chosen from the values of R5 defined in any one of the claims;
- a subject of the present invention is thus the products of general formula (I) as defined above, in which
- R5 more particularly represents a hydrogen atom, a halogen atom or an alkyl, cycloalkyl, —NHR20, —NHCOR20, —NHCONR19R20 or —NH—S(O)2-R20 radical;
- R5 even more particularly represents a hydrogen atom, a halogen atom; an alkyl, cycloalkyl, NH2, —NH-cycloalkyl, —NHCO-alkyl, —NHCO-cycloalkyl, —NHCONH-alkyl or —NHCON(dialkyl) radical, the alkyl and cycloalkyl residues being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms (F) and alkoxy, morpholinyl, piperidyl, piperazinyl, N-methylpiperazinyl and COOH radicals; NH-aryl, NH-heteroaryl, —NHCO-aryl and —NHCO-heteroaryl in which the aromatic residues are optionally substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy and COOH radicals;
- alkyl groups of —NHCON(dialkyl) can be linked together to form a ring that optionally can contain oner or more O, N, S and optionally can be substituted by F or alkyl;
- a subject of the present invention is thus, particularly, the products of formula (I) as defined above corresponding to formula (Ia):
- p represents the integers 0, 1 and 2
- Aa represents phenyl, heteroaryl and a monocyclic or bicyclic fused carbocyclic or heterocyclic 5- to 11-membered radical, optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R3a;
- Xa represents a single bond or the following divalent
- radicals —N(R6a)-; —O—; —C(O)—; —S(O)n-; —N(R6a)-C(O)—; —N(R6a)-C(O)—N(R6′a)-; —N(R6a)-SO2-; —C(O)—N(R6a)-; —SO2—NR6a-;
- L1a represents an alkylene radical containing 1 to 4 carbon atoms and optionally substituted with one or more substituents chosen from the values of R7a;
- radical NR1aR2a is such that:
- R1a and R2a which may be identical or different, are such that:
- R1a represents a hydrogen atom; alkyl and cycloalkyl, these last two radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a; aryl, heteroaryl, arylalkyl and heteroarylalkyl in which each of the aromatic rings may be optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8a;
- R2a represents a hydrogen atom, alkyl and cycloalkyl, these last two radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a;
- R1a and R2a form, together with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, NR12a and S and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a;
- NR1a with L1a or NR2a with L1a together form a 4- to 8-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a;
- R3a represents a hydrogen atom, a halogen atom; an alkyl, cycloalkyl, alkoxy or alkylenedioxy radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a; —NR13aR14a; —C(O)R13a; —S(O) n R13a; —C(O)NR15aR16a; —S(O) n NR15aR16a; aryl and heteroaryl, these last two radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8a;
- R4a, R4a′, R4a′′ and R4a′′′ which may be identical or different, are chosen from the values defined below for R4a;
- R4a represents a hydrogen atom, a halogen atom, an alkyl or cycloalkyl radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a; it being understood that two substituents from among R4a, R4a′ and R4a′′ may form, with the carbon atom(s) to which they are attached, a 3- to 7-membered ring optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and N-alkyl;
- L2a is chosen from a single bond; alkylene; cycloalkylene; —O— and —NR17a-;
- Ya represents an N-heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S and N and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R5a;
- R5a represents a hydrogen atom, a halogen atom
- an alkyl or cycloalkyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a; aryl, arylalkyl, heteroaryl and heteroarylalkyl, in which the aromatic rings are optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8a; —OR18a; —NR19aR20a; —NR19aCOR20a; —NR19aCONR19′aR20a; —NR19a-S(O)2-R20a; —NR19a-S(O)2-NR19a′R20a; —COR18a; COOR21a; —CONR22aR23a; —S(O)nR18a; —SO2NR22aR23a; cyano;
- R6a is such that:
- R6a represents a hydrogen atom or an alkyl or cycloalkyl radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a;
- R6a with NR1aR2a together form a 5- to 7-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a;
- R6a with L1a together form a 5- to 7-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a;
- R6a′ which may be identical to or different from R6a, is chosen from the values of R6a,
- R7a represents a halogen atom; an alkyl; hydroxyl (OH); alkoxy; cycloalkoxy; cyano radical; —CF3; —N24aR25a; —NR26aCOR27a; —NR26aCONR26a′R27a; —NR26a-S(O)2-R27a; —NR26a-S(O)2-NR26a′R27a; —COOR26a; —COR26a; —CO(NR24aR25a); S(O)nR26a; —S(O)2NR24aR25a; a 4- to 7-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from OH and NH2 radicals, halogen atoms, and alkyl, alkoxy or oxo radicals; aryl optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and
- R8a which may be identical to or different from R7a, represents the same values as R7a and also represents halogen atoms, —OCF3, alkylenedioxy and difluoromethylenedioxy radicals;
- R12a represents a hydrogen atom or an alkyl, cycloalkyl, alkylCO or alkylSO 2 radical, all optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkoxy radicals;
- R13a represents an alkyl or cycloalkyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a; a phenyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms, alkyl and alkoxy radicals; a 5- or6-membered heteroaryl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms, alkyl and alkoxy radicals;
- R14a represents an alkyl or cycloalkyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a; C(O)R28a;
- R13a and R14a may optionally form, together with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and Nalkyl and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a;
- R15a and R16a which may be identical to or different from each other and also identical to or different from R13a, are chosen from the same values as R13a and may optionally form, with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms which may be identical or different, chosen from O, S, N and NR12A and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a;
- R17a represents a hydrogen atom or an alkyl or cycloalkyl radical
- R18a which may be identical to or different from R6a, represents the same values as R6a;
- R19a represents a hydrogen atom or an alkyl or cycloalkyl radical
- R20a represents a hydrogen atom or an alkyl or cycloalkyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a; aryl and heteroaryl, optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8a;
- R19a and R20a which may be identical to or different from each other, may also form, with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12a and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a;
- R21a which may be identical to or different from R13a, is chosen from the values of R13a and also represents a hydrogen atom;
- R22a and R23a which may be identical to or different from each other and identical to or different from R6a, are chosen from the values of R6a and may also form, with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR12a and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7a;
- R24a and R25a which may be identical or different, represent an alkyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms, and OH and alkoxy radicals, or alternatively R24a and R25a may optionally form, with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, N-alkyl and N-C(O)alkyl, and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms (F) and OH, alkyl, alkoxy or oxo radicals;
- R26a represents a hydrogen atom or an alkyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms (F) and OH and alkoxy radicals;
- R27a which may be identical to or different from R26a, is chosen from the values of R26a;
- R26a and R27a may also optionally form, with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, N-alkyl and N—C(O)alkyl, and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and OH, alkyl, alkoxy or oxo radicals;
- R28a which may be identical to or different from R26a, is chosen from the values of R26a;
- R29a which may be identical to or different from R26a, is chosen from the values of R26a;
- R30a which may be identical to or different from R26a, is chosen from the values of R26a;
- n the integers 0, 1 and 2;
- p represents the integers 0, 1 and 2;
- a subject of the invention is especially the products of formula (I) as defined above such that p represents the integer 0, the other substituents of the said products of formula (I) each having any one of the values defined in the present invention.
- a subject of the invention is especially the products of formula (I) as defined above such that p represents the integer 1, the other substituents of the said products of formula (I) having any one of the values defined in the present invention.
- a subject of the invention is especially the products of formula (I) as defined above such that p represents the integer 2, the other substituents of the said products of formula (I) having the values defined in the present invention.
- a subject of the present invention is, more particularly, 5 the products of formula (I) or (Ia) as defined above corresponding to formula (Ib):
- Ab represents phenyl, heteroaryl or a carbocyclic or heterocyclic 7- to 11-membered cyclic radical, optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R3b;
- Xb represents a single bond or the following divalent radicals: —N(R6b)-; —O—; —C(O)—; —S(O)n-; —N(R6b)-C(O)— and —N(R6b)-SO2-;
- L1b represents an alkylene radical containing 1 to 4 carbon atoms and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and OH and alkoxy radicals;
- radical NR1bR2b is such that:
- R1b and R2b which may be identical or different, are such that:
- R1b represents a hydrogen atom or an alkyl or cycloalkyl radical, these last two radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7b; aryl and heteroaryl, both optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8b;
- R2b represents a hydrogen atom or an alkyl or cycloalkyl radical, these last two radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7b;
- R1b and R2b form, together with the nitrogen atom to which they are attached, a 4- to 10-membered heterocycle optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, N-alkyl and S and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7b;
- NR1b with L1b or NR2b with L1b together form a 4- to 8-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7b;
- R3b represents a hydrogen atom, an alkyl, alkoxy (—OCH3) or cycloalkyl radical, optionally substituted with one or more fluorine atoms; OCF3 and S(O) n -alkyl radicals, the alkyl residue containing 1 to 4 carbon atoms and being optionally substituted with one or more F; alkylamino, optionally substituted with one or more F; dialkylamino, in which the two alkyl residues may optionally form, with the nitrogen atom to which they are attached, a 4- to 10-membered heterocyclic radical optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, N-alkyl and S and optionally substituted with one or more substituents, which may be identical or different, chosen from F and alkyl and alkoxy radicals;
- R4b and R4′b which may be identical or different, represent a hydrogen atom, a halogen atom F and an alkyl or cycloalkyl radical, optionally substituted with one or more F; it being understood that two substituents R4b may form, with the carbon atom to which they are attached, a 3- to 5-membered spirocyclic ring;
- L2b is chosen from a single bond and methylene
- Yb represents a monocyclic or bicyclic heteroaryl radical chosen from pyridyl, pyrimidinyl, pyridazine, pyrazine, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, isoxazolyl, 1H-pyrrolo[2,3-b]pyridyl, furazanyl, morpholinyl, pyrrolidinyl, indazolyl, 3H-imidazo-(4,5b)-pyridine, 1H-pyrazolo-(3,4b)-pyridine, 1H-pyrazolo-(3,4d)-pyrimidine, piperidyl, thienyl, indolyl, pyrrolyl, purinyl, benzoxazinyl, benzimidazolyl, these radical
- R5b represents a hydrogen atom; a halogen atom; alkyl; cycloalkyl; —NHR20b; —NHCOR20b; —NHCONR19bR20b; —NH—S(O)2-R20b;
- R6b represents a hydrogen atom or an alkyl radical containing from 1 to 4 carbon atoms
- R6b and NR1bR2b may optionally together form a 5- to 7-membered heterocycle optionally substituted with one or more radicals, which may be identical or different, chosen from the values of R7b;
- R7b represents a halogen atom ; hydroxyl; cyano; COOH; —CF3; alkyl, alkoxy, alkylamino, dialkylamino, —NHCO-alkyl, —CO(NH-alkyl) and CO(Ndialkyl) in which the alkyl residues are optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms, OH and methoxy; an aryl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkyl and alkoxy radicals; a 4- to 7-membered heterocycle; heteroaryl, optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and NH2, alkyl and alkoxy radicals;
- R8b which may be identical to or different from R7b, is chosen from the values of R7b and in addition represents halogen atoms and —OCF3, alkylenedioxy and difluoromethylenedioxy radicals;
- R19b represents a hydrogen atom or an alkyl or cycloalkyl radical
- R20b represents a hydrogen atom or an alkyl or cycloalkyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7b; aryl and heteroaryl, optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R8b;
- R19b and R20b which may be identical to or different from each other, may also form, with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and Nalkyl and optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R7b;
- n the integers 0, 1 and 2;
- a subject of the present invention is, even more particularly, the products of formula (I), (Ia) or (Ib) as defined above, corresponding to formula (Ic):
- A represents a phenyl, a 5 to 6-membered heteroaryl or a condensed heterocyclic ring system selected from the list: 1,2,3,4-tetrahydro-quinolin, 1,2,3,4-tetrahydro-isoquinolin, indolyl, 2,3-dihydro-1H-indolyl, 2,3-dihydro-1H-isoindolyl, 2,3-dihydro-benzothiazole, tetrahydroquinoline or tetrahydroisoquinoline;
- radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from alkyl, alkoxy, cycloalkyl, alkylamino and dialkylamino radicals, each alkyl radical being optionally substituted with one or more F; —OCF3, SCF3 and SO2CF3 radicals;
- Xc represents a single bond or the following divalent radicals: —N(R6c)-; —O—; —C(O)—; and —N(R6c)-C(O)—;
- L1c represents an alkylene radical containing 1 to 4 carbon atoms, optionally substituted with a hydroxyl radical
- R1c and R2c which may be identical or different, are such that:
- R1c represents an alkyl or cycloalkyl radical optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms; hydroxyl; alkoxy; cyano, free or esterified carboxyl, phenyl, 3- to 7-membered cycloalkyl, alkylamino, dialkylamino, —NHCO-alkyl, —CO(NH-alkyl), CO(Ndialkyl) and saturated, partially saturated or unsaturated 5-, 6- or7-membered heteroaryl radicals containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, NH and N-alkyl and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkyl, NH2 and alkoxy radicals; or alternatively R1c represents a phenyl radical or a saturated, partially saturated or unsaturated 4- to 7-membered hetero
- R2c represents a hydrogen atom or an alkyl or cycloalkyl radical optionally substituted with one or more halogen atoms;
- R1c and R2c form, together with the nitrogen atom to which they are attached, a 4- to 7-membered heterocycle optionally containing one or more other hetero atoms, which may be identical or different, chosen from O, N, NH, N-alkyl and S and optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms and alkyl, alkoxy, CF3 and free or esterified carboxyl radicals;
- NR1c with L1c or NR2c with L1C together form a 4- to 7-membered heterocycle optionally substituted with one or more substituents, which may be identical or different, chosen from halogen atoms, and alkyl, alkoxy and free or esterified carboxyl radicals;
- L2c is chosen from a single bond and methylene
- R4c and R4′c which may be identical or different, represent a hydrogen atom, an alkyl or cycloalkyl radical optionally substituted with one or more halogen atoms; it being understood that two substituents R4c may form, with the carbon atom to which they are attached, a 3-membered to 5-membered spirocyclic ring;
- Yc represents a heteroaryl radical chosen from pyrid-4-yl, pyrimidin-4-yl, quinolin-4-yl, isoquinolin-5-yl; azaindol-4-yl and quinazolin-4-yl, these radicals being optionally substituted with one or more substituents, which may be identical or different, chosen from the values of R5c;
- R5c represents a hydrogen atom, a halogen atom; an alkyl, cycloalkyl, NH2, —NH-cycloalkyl, —NHCO-alkyl, —NHCO-cycloalkyl, —NHCONH-alkyl or —NHCON(dialkyl) radical, the alkyl and cycloalkyl residues being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms (F) and alkoxy, morpholinyl, piperidyl, piperazinyl, N-methyl-piperazinyl and COOH radicals; NH-aryl, NH-heteroaryl, —NHCO-aryl and —NHCO-heteroaryl in which the aromatic residues are optionally substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy and COOH radicals;
- R6c represents a hydrogen atom or an alkyl radical containing from 1 to 4 carbon atoms
- R6c and NR1cR2c may optionally together form a 5- to 7-membered heterocycle optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms (F) and alkyl and alkoxy radicals,
- a subject of the present invention is, particularly, the products of formula (I) as defined above in which A represents a phenyl, 2,3-dihydro-1H-indolyl, or indolyl radical optionally substituted with one or more radicals chosen from the values of R3,
- X represents a single bond, —NH-alk-, alkylene, —O—, —Nalk-CO—, —NH—CO, —NH—CO-alk-, —NH—CO—NH—, —CO—NH—, —SO2, —NR6d or —CO—,
- L1 represents a single bond, an alkylene radical containing 1 to 5 carbon atoms optionally substituted with a hydroxyl radical, an cycloalkylalkyl radical, a phenyl radical,
- R1 and R2 which may be identical or different, are such that:
- R1 represents a hydrogen atom, an alkyl radical optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkoxy, NH2, NH(alk), N(alk)2, cyano, free or esterified carboxyl, phenyl and 3- to 7-membered cycloalkyl radicals and a saturated, partially saturated or unsaturated 4- to 7-membered heterocyclic radical, itself optionally substituted with one or more alkyl radicals and containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, NH and N-alkyl,
- R1 represents a 3- to 7-membered cycloalkyl radical, a phenyl radical or a saturated, partially saturated or unsaturated 4- to 7-membered heterocyclic radical, itself optionally substituted with one or more alkyl radicals and containing one or more hetero atoms chosen from O, S, N, NH and N-alkyl,
- R2 represents a hydrogen atom or an alkyl radical, or R1 and R2 form, with the nitrogen atom to which they are attached, a saturated or unsaturated 4- to 7-membered heterocyclic radical optionally containing one or more other hetero atoms chosen from O, S, N, NH and N-alkyl, this radical formed by R1 and R2 with N being itself optionally substituted with one or more radicals chosen from alkyl, halogen, NH2, NH(alk), N(alk)2, CF3 and free or esterified carboxyl radicals,
- NR1R2 forms with L1 a saturated or unsaturated 4- to -10-membered heterocycle containing at least one nitrogen atom and optionally containing one or more other hetero atoms chosen from O, S, N, NH and N-alkyl, this radical formed by NR1R2 with L1 being itself optionally substituted with one or more radicals chosen from alkyl, cycloalkyl and free or esterified carboxyl radicals,
- R3 represents one or more substituents of the ring A, which may be identical or different, chosen from a hydrogen atom and an alkyl or alkoxy radical containing up to 4 carbon atoms, optionally substituted with one or more F; alkyl-S(O)n optionally substituted by F; OCF3;SO2CF2; or SCF3; with n representing 0 or 2;
- R4 and R4′ which may be identical or different, are chosen from a hydrogen atom and an alkyl radical containing up to 4 carbon atoms,
- R6 represents a hydrogen atom, an acyl radical optionally substituted with one or more F or an alkyl radical containing from 1 to 4 carbon atoms,
- L2 represents an alkylene radical
- Y2 represents a quinolyl, pyridyl or pyrimidinyl radical, optionally substituted by NH2;
- a subject of the present invention is, most particularly, the products of formula (I) as defined above corresponding to formula (Id):
- Ad represents a phenyl or indolyl radical optionally substituted with one or more radicals chosen from the values of R3d,
- Xd represents —O—, —NH—CO, —NR6 or —CO—
- L1d represents an alkylene radical containing 1 to 3 carbon atoms optionally substituted with a hydroxyl radical
- R1d and R2d which may be identical or different, are such that:
- R1d represents an alkyl radical optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkoxy, cyano, free or esterified carboxyl, phenyl and 3- to 7-membered cycloalkyl radicals and a saturated, partially saturated or unsaturated 4- to 7-membered heterocyclic radical, itself optionally substituted with one or more alkyl radicals and containing one or more hetero atoms, which may be identical or different, chosen from O, S, N, NH and N-alkyl,
- R1d represents a 3- to 7-membered cycloalkyl radical, a phenyl radical or a saturated, partially saturated or unsaturated 4- to 7-membered heterocyclic radical, itself optionally substituted with one or more alkyl radicals and containing one or more hetero atoms chosen from O, S, N, NH and N-alkyl,
- R2d represents a hydrogen atom or an alkyl radical
- R1d and R2d form, with the nitrogen atom to which they are attached, a saturated or unsaturated 4- to 7-membered heterocyclic radical optionally containing one or more other hetero atoms chosen from O, S, N, NH and N-alkyl, this radical formed by R1d and R2d with N being itself optionally substituted with one or more radicals chosen from alkyl, CF3 and free or esterified carboxyl radicals,
- NR1dR2d forms with L1d a saturated or unsaturated 4- to 8-membered heterocycle containing at least one nitrogen atom and optionally containing one or more other hetero atoms chosen from O, S, N, NH and N-alkyl, this radical formed by NR1dR2d with L1d being itself optionally substituted with one or more radicals chose from alkyl and free or esterified carboxyl radicals,
- R3d represents one or more substituents of the ring Ad, which may be identical or different, chosen from a hydrogen atom and an alkyl or alkoxy radical containing up to 4 carbon atoms, optionally substituted with one or more F; OCF3; SO2CF3; or SCF3;
- R4d and R4′d which may be identical or different, are chosen from a hydrogen atom and an alkyl radical containing up to 4 carbon atoms,
- L2d represents an alkylene radical
- Y2d represents a quinolyl, pyridyl or pyrimidinyl radical
- R1d and R2d are especially such that:
- R1d and R2d which may be identical or different, are such that:
- R1d represents an alkyl radical (1 to 6C) optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl; alkoxy; cyano; free and esterified carboxyl; phenyl; cyclopropyl, cyclopentyl, cyclohexyl, isoxazolyl, furyl, pyrazinyl, morpholinyl, pyridyl and isothiazolyl radicals, optionally substituted with one or more alkyl radicals,
- R2a represents a cyclopropyl, cyclopentyl, cyclohexyl, phenyl, hexahydropyran, pyrrolidinyl, piperidyl or pyridyl radical optionally substituted with one or more alkyl radicals,
- R2d represents a hydrogen atom or an alkyl radical
- R1d and R2d form, with the nitrogen atom to which they are attached, a morpholinyl, piperidyl, piperazinyl or pyrrolidinyl radical, optionally substituted with one or more radicals chosen from alkyl, CF3 and free or esterified carboxyl radicals,
- L1d a piperidyl radical optionally substituted with one or more radicals chosen from alkyl and free or esterified carboxyl radicals.
- a subject of the present invention is especially the products of formula (I), (Ia), (Ib), (Ic) or (Id) as defined above in which, when A represents a phenyl radical, then X represents —O—, —NR6 or —NH—CO, the other substituents of the said products of formula (I), (Ia), (Ib), (Ic) or (Id) being chosen from all the values defined for the said substituents,
- a subject of the present invention is also especially the products of formula (I), (Ia), (Ib), (Ic) or (Id) as defined above in which, A represents an indolinyl radical, X represents —O—, —NR6, —CO— or —NR6-CO and the other substituents of the said products of formula (I), (Ia), (Ib), (Ic) or (Id) being chosen from all the values defined for the said substituents,
- a subject of the present invention is, more specifically,
- an intermediate of general formula 1a in which the variables have the abovementioned meanings and in which X′ denotes NH2, OH or SH, is reacted with a difunctional alkylating agent of general formula 1b, for instance a haloalkanal acetal.
- a difunctional alkylating agent of general formula 1b for instance a haloalkanal acetal.
- the reaction is performed in bulk or in an inert organic solvent, optionally in the presence of a base.
- a preferred alkylating agent is bromoacetaldehyde diethyl acetal.
- One variant for access to I describes the direct alkylation of compounds of general formula 1a with an aminoalkyl halide of general formula Ha1-L 1 -N(R1R2).
- this reaction is preferably performed in an organic solvent such as ethyl acetate, DMF, NMP or acetone, in the presence of a base such as potassium tert-butoxide, potassium carbonate or caesium carbonate.
- a base such as potassium tert-butoxide, potassium carbonate or caesium carbonate.
- X′ denotes NH2
- the process preferably proceeds first with acylation and the intermediate amide is used for the alkylation.
- Preferred acyl radicals are acetyl and trifluoroacetyl. Removal of the acyl group once the alkylation has been performed then gives rise to compounds according to the invention, which may be optionally converted into compounds of general formula Ic via additional steps.
- the starting substances of general formula 1a (X′ ⁇ NH2) required for this sequence may be prepared in accordance with the process summarized in Scheme 2.
- a suitably substituted nitroaniline which may be obtained, for example, by nitration of the corresponding aniline, is, in the present case, converted into the corresponding isocyanate or into a derivative of similar reactivity, in an inert solvent under the action of phosgene, diphosgene, triphosgene or carbonyldiimidazole, in the presence or absence of an auxiliary base, and reacted with a compound of general formula 2a to give rise to the heterocyclic compounds of general formula 2b.
- 2a are preferably obtained by reductive amination of the corresponding amino acid derivative with an aldehyde of general formula R5-Y-L 2 ′-CHO.
- the intermediates of general formula 1a may also be prepared by direct nitration of compounds of general formula 2c.
- the subsequent reduction of the nitro compound 2b is performed by catalytic hydrogenation in the presence of a heterogeneous or homogeneous transition metal catalyst, preferably a heterogeneous transition metal catalyst.
- a heterogeneous or homogeneous transition metal catalyst preferably a heterogeneous transition metal catalyst.
- the reduction may also be performed with a non-precious metal in the presence of an acid.
- Preferred reagents for this reaction are zinc and dilute hydrochloric acid, particularly preferably zinc and glacial acetic acid.
- constituent components of general formula 1a are obtained when a correspondingly substituted synthon 3a, optionally protected on reactive groups, is converted into the corresponding isocyanate or into a derivative of similar reactivity, under the action of phosgene, diphosgene, triphosgene or carbonyldiimidazole, in the presence or absence of an auxiliary base, and condensed with an amino acid derivative of general formula 2b, in an inert solvent, for instance THF, toluene, dioxane or ethyl acetate, optionally in the presence of an auxiliary base, for instance triethylamine or potassium tert-butoxide.
- the reaction temperature is preferably between room temperature and the reflux point of the solvent, particularly preferably at the reflux point.
- the cyclization may also be performed in aqueous-acidic solution at elevated temperature.
- One variant of the process for preparing the compounds of general formulae Ia, Ib and Ic, in which X′ denotes NR6, O or S, consists in converting the constituent components of general formulae 3a-d into the corresponding isocyanate or into a derivative of similar reactivity, with phosgene, diphosgene, triphosgene or carbonyldiimidazole, in the presence or absence of an auxiliary base, and in then reacting them with an amino acid derivative of general formula 2a under the conditions mentioned for the preparation of 1a.
- the intermediates thus obtained are then converted into compounds of general formulae Ia-c in a manner similar to that for the reactions described in Scheme 1.
- the arylamines 3a are in part described in the literature or may be obtained in accordance with conversions known to those skilled in the art from derivatives known in the literature.
- the starting substances 3b-e are obtained from 3a via synthetic routes that are in principle similar to the reaction sequences described in Scheme 1.
- the free amino group is, in the present case, protected with the usual protecting groups or masked in the form of a nitro function, and reduced at a subsequent stage.
- Preferred reagents are chloroacetyl chloride, acryloyl chloride, 2-chloropropionyl chloride and chloromethanesulphonyl chloride, and also homologues thereof.
- the coupling is preferably performed in an inert solvent at low temperature.
- the use of a base is optional.
- the compounds of general formula Id are obtained by reaction with a suitably substituted amine. This reaction may be performed in an inert organic solvent or in bulk, optionally in the presence of an auxiliary base.
- aminopropionylamides according to the invention are obtained after reaction with amines.
- 4a may also be reacted directly with amino-substituted difunctional reagents of general formula 4b to give rise to compounds of general formula Id.
- the compounds of general formula I in which X denotes —N(R6)-C(O)— and R2 and L1 form a nucleus are obtained by reacting compounds of general formula 4a with an activated amino acid derivative of general formula 5.
- the amino acid may be activated by conversion into the acid chloride or via amide coupling reactions that are sufficiently known to those skilled in the art.
- the products initially obtained, Ie may be converted into other compounds Ie according to the invention via other conversions.
- 6b is first activated by the action of agents such as, for example, thionyl chloride, oxalyl chloride or phosphorus pentachloride.
- agents such as, for example, thionyl chloride, oxalyl chloride or phosphorus pentachloride.
- the activation may also be performed with coupling agents known to those skilled in the art, for instance TOTU or DCC.
- Scheme 6 illustrates, by way of example, the way in which compounds in which A denotes a system containing a fused homocyclic or heterocyclic nucleus may be prepared.
- nucleus A is first linked to the central heterocycle in accordance with the reaction sequence described for compound 2b.
- the compounds of general formula I are then obtained by alkylation, acylation, sulphonylation, carbamoylation or thiocarbamoylation and additional reactions of the derivatives thus obtained.
- the compounds of general formula I may moreover be obtained by reacting an amino acid derivative of general formula 7a with an isocyanate 7b or an analogue of similar reactivity, in which Z denotes a group A-, R3A- or R3A(X′)- or denotes
- the intermediates 7c formed are then converted into compounds of general formula I by alkylation with a halide Hal-L 2 -Y-R5 or another reagent of similar reactivity.
- the alkylation reactions are preferably performed in an organic solvent, for instance dimethylformamide, N-methylpyrrolidone, ethyl acetate or acetone, in the presence of a base, for instance potassium carbonate, caesium carbonate, sodium hydride or potassium tert-butoxide.
- a base for instance potassium carbonate, caesium carbonate, sodium hydride or potassium tert-butoxide.
- the bases dimethylformamide and caesium carbonate are preferably used.
- the compounds of formula (I) may be purified via common purification procedures, for example by recrystallization or chromatography.
- the starting materials for the preparation of the compounds of formula (I) are commercially available or may be prepared in accordance with or analogously to literature procedures.
- the compounds obtained via the abovementioned synthetic methods constitute an additional subject of the present invention.
- the products that are the subject of the present invention are endowed with advantageous pharmacological properties: it has been found that they especially have inhibitory properties on protein kinases.
- IGF1R insulin growth factor receptor
- the products of formula (I) may also be used in the veterinary field.
- One subject of the invention is thus, as medicinal products, the products of formula (I) as defined above, and also prodrugs thereof, the said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the pharmaceutically acceptable addition salts with mineral and organic acids or with mineral and organic bases of the said products of formula (I).
- a subject of the invention is thus the use, as medicinal products, of the products of formula (Ia), (Ib), (Ic) or (Id) as defined above, and also prodrugs thereof, the said products of formula (Ia), (Ib), (Ic) or (Id) being in all the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the pharmaceutically acceptable addition salts with mineral and organic acids or with mineral and organic bases of the said products of formula (Ia), (Ib), (Ic) or (Id).
- a subject of the invention is thus, most particularly, the use, as medicinal products, of the products of formula (I), the names of which are given hereinbelow:
- a subject of the invention is thus, most particularly, the use, as medicinal products, of the products of formula (I), the names of which are given hereinbelow:
- the products may be administered via the parenteral, buccal, perlingual, rectal or topical route.
- a subject of the invention is thus pharmaceutical compositions, characterized in that they contain, as active principle, at least one of the medicinal products of formula (I) as defined above.
- compositions may be in the form of injectable solutions or suspensions, tablets, coated tablets, capsules, syrups, suppositories, creams, ointments and lotions.
- These pharmaceutical forms are prepared according to the usual methods.
- the active principle may be incorporated into excipients usually used in these compositions, such as aqueous or nonaqueous vehicles, talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, fatty substances of animal or plant origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, and preserving agents.
- the usual dose which varies according to the individual treated and the complaint under consideration, may be, for example, from 10 mg to 500 mg per day orally in man.
- the present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) for the preparation of medicinal products for inhibiting the activity of protein kinases and especially of a protein kinase.
- the present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) in which the protein kinase is a protein tyrosine kinase.
- the present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) in which the protein kinase is chosen from the following group: IGF1, Raf, EGF, PDGF, VEGF, Tie2, KDR, Flt1-3, FAK, Src, Ab1, cKit, cdk1-9, Aurora1-2, cdc7, Akt, Pdk, S6K, Jnk, IR, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, PLK, Pyk2, CDK7, CDK2 et EGFR.
- the protein kinase is chosen from the following group: IGF1, Raf, EGF, PDGF, VEGF, Tie2, KDR, Flt1-3, FAK, Src, Ab1, cKit, cdk1-9, Aurora1-2, cdc7, Akt, Pdk, S6K,
- protein kinase is chosen from the following group:
- the present invention thus relates particularly to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) in which the protein kinase is IGF1R.
- the present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) in which the protein kinase is FAK.
- the present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) in which the protein kinase is AKT.
- the present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) in which the protein kinase is in a cell culture, and also to this use in a mammal.
- the present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) for the preparation of a medicinal product for preventing or treating a disease characterized by deregulation of the activity of a protein kinase and especially such a disease in a mammal.
- the present invention relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) for the preparation of a medicinal product for preventing or treating a disease belonging to the following group: disorders of blood vessel proliferation, fibrotic disorders, disorders of mesangial cell proliferation, acromegaly, metabolic disorders, allergies, asthma, Crohn's disease, thrombosis, diseases of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, aging, age related macula degeneration, oncology diseases and cancer.
- a disease belonging to the following group: disorders of blood vessel proliferation, fibrotic disorders, disorders of mesangial cell proliferation, acromegaly, metabolic disorders, allergies, asthma, Crohn's disease, thrombosis, diseases of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, aging, age related
- the present invention thus relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) for the preparation of a medicinal product for treating oncology diseases.
- the present invention relates particularly to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) for the preparation of a medicinal product for treating cancers.
- the present invention is most particularly of interest in the treatment of solid tumours and the treatment of cancers that are resistant to cytotoxic agents.
- the present invention relates most particularly to the treatment of breast cancer, stomach cancer, cancer of the colon, lung cancer, cancer of the ovaries, cancer of the uterus, brain cancer, cancer of the kidney, cancer of the larynx, cancer of the lymphatic system, cancer of the thyroid, cancer of the urogenital tract, cancer of the tract including the seminal vesicle and prostate, bone cancer, cancer of the pancreas and melanomas.
- the present invention is even more particularly of interest in treating breast cancer, cancer of the colon and lung cancer.
- the present invention also relates to the use of products of formula (I) as defined above or of pharmaceutically acceptable salts of the said products of formula (I) for the preparation of a medicinal product for cancer chemotherapy.
- products of formula (I) according to the present invention may be used alone or in combination with chemotherapy or radiotherapy or alternatively in combination with other therapeutic agents.
- the present invention thus relates especially to the pharmaceutical compositions as defined above, characterized in that they are used as medicinal products, in particular for cancer chemotherapy.
- the present invention thus relates especially to the pharmaceutical compositions as defined above containing, in addition to the active principles, other chemotherapy medicinal products for combating cancer.
- Such therapeutic agents may be commonly used antitumour agents.
- inhibitors of protein kinases mention may be made especially of butyrolactone, flavopiridol, 2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine, olomucine, Glivec and Iressa.
- the products of formula (I) according to the present invention may thus also be advantageously used in combination with antiproliferative agents: as examples of such antiproliferative agents, but without, however, being limited to this list, mention may be made of aromatase inhibitors, antioestrogens, the topoisomerase I inhibitors, the topoisomerase II inhibitors, microtubule-active agents, alkylating agents, histone deacetylase inhibitors, farnesyl transferase inhibitors, COX-2 inhibitors, MMP inhibitors, mTOR inhibitors, antineoplastic antimetabolites, platinum compounds, compounds that reduce the activity of protein kinases and also anti-angiogenic compounds, gonadorelin agonists, antiandrogens, bengamides, biphosphonates and trastuzumab.
- antiproliferative agents examples of such antiproliferative agents, but without, however, being limited to this list, mention may be made of aromatase inhibitors, antioestrogens
- anti-microtubule agents for instance taxoids, vinca alkaloids, alkylating agents such as cyclophosphamide, DNA-intercalating agents, for instance cis-platinum, agents that are interactive on topoisomerase, for instance camptothecin and derivatives, anthracyclines, for instance adriamycin, antimetabolites, for instance 5-fluorouracil and derivatives, and the like.
- the present invention thus relates to products of formula (I) as protein kinase inhibitors, the said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts of the said products of formula (I) with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases, and also the prodrugs thereof.
- the present invention relates particularly to products of formula (I) as defined above as IGF1R inhibitors.
- the present invention also relates to products of formula (I) as defined above as FAK inhibitors.
- the present invention also relates to products of formula (I) as defined above as AKT inhibitors.
- the present invention relates more particularly to the products of formula (Ia), (Ib), (Ic) and in particular (Id) as defined above as IGF1R inhibitors.
- the title compound was prepared as described for example 17 using glycimethylester hydrochloride and Hünig's base in DMF.
- the title compound was prepared as described for example 1e using 1 ml homomorpholine hydrochlorid and Hünig's base.
- the title compound was prepared as described for example 1e using 2-fluoroethylamine hydrochlorid and Hünig's base.
- the title compound was prepared as described for example 2 using 150 mg N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-chloro-acetamide (raw material as described above) and 1 ml of the appropriate amine.
- the raw material was purified by preparative HPLC. (C18 reversed phase column, elution with a water (0.1% trifluoracetic acid)/acetonitrile gradient)
- the title compound was prepared as described for example 2 using 150 mg N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-chloro-acetamide (raw material as described above) (raw amterial as described above) and 1 ml of the appropriate amine.
- the raw material was purified by preparative HPLC. (C18 reversed phase column, elution with a water (0.1% trifluoracetic acid)/acetonitrile gradient) Yield: 80 mg
- the title compound was prepared as described for example 2 using 150 mg N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-chloro-acetamide (raw material as described above) and 1 ml of the appropriate amine.
- the raw material was purified by preparative HPLC. (C18 reversed phase column, elution with a water (0.1% trifluoracetic acid) /acetonitrile gradient)
- the title compound was prepared as described for example 2 using 150 mg N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-chloro-acetamide (raw material as described above) and 1 ml of a 2 m solution of dimethylamine in DMF. The raw material was purified by preparative HPLC. (C18 reversed phase column, elution with a water (0.1% trifluoracetic acid)/acetonitrile gradient) Yield: 25 mg
- the title compound was prepared as described for example 2 using 150 mg N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-chloro-acetamide (raw material as described above) and 1 ml of the appropriate amine.
- the raw material was purified by preparative HPLC. (C18 reversed phase column, elution with a water (0.1% trifluoracetic acid)/acetonitrile gradient)
- the title compound was prepared as described for example 2 using 150 mg N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-chloro-acetamide (raw material as described above) and 1 ml of the appropriate amine.
- the raw material was purified by preparative HPLC. (C18 reversed phase column, elution with a water (0.1% trifluoracetic acid)/acetonitrile gradient)
- the title compound was prepared as described for example 2 using 150 mg N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-chloro-acetamide (raw material as described above) and 1 ml of the appropriate amine.
- the raw material was purified by preparative HPLC. (C18 reversed phase column, elution with a water (0.1% trifluoracetic acid)/acetonitrile gradient)
- the product was obtained as its trifluoroacetate salt.
- the product was obtained as its trifluoroacetate salt.
- the product was obtained as its trifluoroacetate salt.
- the product was obtained as its trifluoroacetate salt.
- the product was obtained as its trifluoroacetate salt.
- the product was obtained as its trifluoroacetate salt.
- the product was obtained as its trifluoroacetate salt.
- the product was obtained as its trifluoroacetate salt.
- the title compound was prepared in analogy to example 51e by using 100 mg [5-(4,4-dimethyl-2,5-dioxo-3-quinolin-4-ylmethyl-imidazolidin-1-yl)-2-methoxy-phenoxy]-acetaldehyde as starting material and 4-amino-1-methylpiperidine instead of morpholine.
- the title compound was prepared in analogy to example 51e by using 70 mg [5-(4,4-dimethyl-2,5-dioxo-3-quinolin-4-ylmethyl-imidazolidin-1-yl)-2-methoxy-phenoxy]-acetaldehyde as starting material and 3-amino-pyrrolidine-1-carboxylic acid tert-butyl ester instead of morpholine.
- the product was obtained as its trifluoroacetate salt. Yield: 44 mg
- the following compound was prepared in analogy to example 72 by using 3-amino-pyrrolidine-1-carboxylic acid tert-butyl ester instead of tetrahydro-pyran-4-ylamine.
- the crude product was dissolved in 2 ml of a 8 N solution of hydrochloric acid in methanol and the resulting solution was stirred for 1 hour at room temperature. After removal of the solvent under reduced pressure the residue was dissolved in a mixture of 2 ml water and 1 ml acetonitrile. After lyophilisation of the solution the residue was purified in addition by preparative HPLC (C18 reverse phase column, elution with a water/acetonitrile gradient with 0.1% trifluoroacetic acid). Lyophilization of the solution yielded a white solid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
-
- the term “Hal”, “Halo” or halogen denotes fluorine, chlorine, bromine or iodine atoms,
- the term “alkyl radical”, “alk”, “Alk” or “ALK” denotes a linear or branched radical containing not more than 12 carbon atoms, chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, sec-pentyl, tert-pentyl, neopentyl, hexyl, isohexyl, sec-hexyl, tert-hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl radicals, and also the linear or branched positional isomers thereof.
-
- the term “alkenyl radical” denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 4 carbon atoms, chosen, for example, from the following values: ethenyl or vinyl, propenyl or allyl, 1-propenyl, n-butenyl, i-butenyl, 3-methyl-2-butenyl, n-pentenyl, hexenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl, and also the linear or branched positional isomers thereof.
-
- the term “alkynyl radical” denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 4 carbon atoms, chosen, for example, from the following values: ethynyl, propynyl or propargyl, butynyl, n-butynyl, i-butynyl, 3-methyl-2-butynyl, pentynyl or hexynyl, and also the linear or branched positional isomers thereof.
-
- the term “alkoxy radical” denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 6 carbon atoms chosen, for example, from methoxy, ethoxy, propoxy, isopropoxy, linear, secondary or tertiary butoxy, pentoxy, hexoxy and heptoxy radicals, and also the linear or branched positional isomers thereof,
- the term “alkoxycarbonyl radical” or alkyl-O—CO— denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above: examples that may be mentioned include methoxycarbonyl and ethoxycarbonyl radicals,
- the term “alkylenedioxy radical” or —O-alkylene-O— denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkylene radical has the meaning given above: examples that may be mentioned include methylenedioxy and ethylenedioxy radicals,
- the term “alkylsulphinyl” or alkyl-SO— denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms,
- the term “alkylsulphonyl” or alkyl-SO2-denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms,
- the term “alkylsulphonylcarbamoyl” or alkyl-SO2-NH—C(═O)— denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms,
- the term “alkylthio” or alkyl-S— denotes a linear or branched radical containing not more than 12 carbon atoms and especially represents methylthio, ethylthio, isopropylthio and heptylthio radicals,
- the term “cycloalkyl radical” denotes a 3- to 10-membered monocyclic or bicyclic carbocyclic radical and especially denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals,
- the term “—O-cycloalkyl radical” denotes a radical in which the cycloalkyl radical has the meaning given above,
- the term “cycloalkenyl radical” denotes a 3- to 10-membered monocyclic or bicyclic nonaromatic carbocyclic radical containing at least one double bond, and especially denotes cyclobutenyl, cyclopentenyl and cyclohexenyl radicals,
- the term “cycloalkylalkyl radical” denotes a radical in which cycloalkyl and alkyl are chosen from the values indicated above: this radical thus denotes, for example, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl radicals,
- the term “acyl radical” or r-CO— denotes a linear or branched radical containing not more than 12 carbon atoms, in which the radical r represents a hydrogen atom or an alkyl, cycloalkyl, cycloalkenyl, cycloalkyl, heterocycloalkyl or aryl radical, these radicals having the values indicated above and being optionally substituted as indicated: examples that are mentioned include the formyl, acetyl, propionyl, butyryl or benzoyl radicals, or alternatively valeryl, hexanoyl, acryloyl, crotonoyl or carbamoyl,
- the term “acyloxy radical” means acyl-O— radicals in which acyl has the meaning given above: examples that are mentioned include acetoxy or propionyloxy radicals,
- the term “acylamino radical” means acyl-NH— radicals in which acyl has the meaning given above,
- the term “aryl radical” denotes unsaturated monocyclic radicals or unsaturated radicals consisting of fused carbocyclic rings. Examples of such aryl radicals that may be mentioned include phenyl or naphthyl radicals.
-
- the term “arylalkyl” means radicals resulting from the combination of the optionally substituted alkyl radicals mentioned above and the optionally substituted aryl radicals also mentioned above: examples that are mentioned include benzyl, phenylethyl, 2-phenethyl, triphenylmethyl or naphthalenemethyl radicals,
- the term “heterocyclic radical” denotes a saturated (heterocycloalkyl) or partially saturated or unsaturated (heteroaryl) 5- to 10-membered radical containing one or more hetero atoms, which may be identical or different, chosen from oxygen, nitrogen and sulphur atoms: the term “heterocyclic” preferably represents a saturated or partially unsaturated 4- to 7-membered heterocyclic radical optionally containing one or more hetero atoms, which may be identical or different, chosen from N, O and S.
-
- the term “heterocycloalkylalkyl radical” means radicals in which the heterocycloalkyl and alkyl residues have the above meanings;
- among the 5-membered heteroaryl radicals that may be mentioned are furyl radicals such as 2-furyl, thienyl radicals such as 2-thienyl and 3-thienyl, and pyrrolyl, diazolyl, thiazolyl, thiadiazolyl, thiatriazolyl, isothiazolyl, oxazolyl, oxadiazolyl, 3- or 4-isoxazolyl, imidazolyl, pyrazolyl and isoxazolyl radicals.
-
- as fused heteroaryl radicals containing at least one hetero atom chosen from sulphur, nitrogen and oxygen, examples that may be mentioned include benzothienyl such as 3-benzothienyl, benzofuryl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzoxazolyl, azaindolyl, thionaphthyl, indolyl, purinyl, quinolyl, isoquinolyl and naphthyridinyl.
-
- among the salification compounds, mineral bases such as, for example, one equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium, or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N-dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine or N-methylglucamine,
- among the esterification compounds, alkyl radicals to form alkoxycarbonyl groups such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, these alkyl radicals possibly being substituted with radicals chosen, for example, from halogen atoms and hydroxyl, alkoxy, acyl, acyloxy, alkylthio, amino or aryl radicals, such as, for example, in chloromethyl, hydroxypropyl, methoxymethyl, propionyloxymethyl, methylthiomethyl, dimethylaminoethyl, benzyl or phenethyl groups.
-
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-morpholin-4-yl-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(dimethyl-morpholin-4-yl)-acetamide trifluoroacetate
- 2-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2,2,2-trifluoro-ethylamino)-acetamide trifluoroacetate
- 2-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-thiomorpholin-4-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-pyrrolidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-piperazin-1-yl)-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-piperidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-2-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-3-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-4-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-hydroxyethylamino)-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-methoxyethylamino)-acetamide trifluoroacetate
- 2-Dimethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- 2-(Cyanomethyl-amino)-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-[1,4]diazepan-1-yl)-acetamide trifluoroacetate
- 2-tert-Butylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(1,2,2-trimethyl-propylamino)-acetamide trifluoroacetate
- ({[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-amino)-acetic acid methyl ester; compound with trifluoro-acetic acid
- 2-(2,2-Difluoro-ethylamino)-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide; compound with trifluoro-acetic acid
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4,4-dimethyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-trifluoromethyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[1,4]oxazepan-4-yl-acetamide
- 1-{[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-pyrrolidine-3-carboxylic acid methyl ester
- 2-Azetidin-1-yl-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-fluoro-ethylamino)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(2-methoxy-ethyl)-methyl-amino]-acetamide
- ({[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-amino)-acetic acid trifluoroacetate
- 2-Cyclohexylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- 2-Cyclopropylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-morpholin-4-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(dimethyl-morpholin-4-yl)-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(4-methyl-piperazin-1-yl)-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-piperidin-1-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-thiomorpholin-4-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-pyrrolidin-1-yl-propionamide trifluoroacetate
- 3-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(2,2,2-trifluoro-ethylamino)-propionamide; compound with trifluoro-acetic acid
- 3-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-morpholin-4-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-piperidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-(4-methyl-piperazin-1-yl)-acetamide trifluoroacetate
- 2-Dimethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-tert-Butylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 1-Methyl-piperidine-4-carboxylic acid [5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-amide, trifluoro-acetate
- 3-[3-(2-Cyclopentylamino-ethoxy)-4-methoxy-phenyl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-(3-{2-[(Furan-2-ylmethyl)-amino]-ethoxy}-4-methoxy-phenyl)-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{3-[2-(2-Hydroxy-1-phenyl-ethylamino)-ethoxy]-4-methoxy-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-[3,3-Dimethyl-1-(2-morpholin-4-yl-acetyl)-2,3-dihydro-1H-indol-6-yl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-[3,3-Dimethyl-1-(2-thiomorpholin-4-yl-acetyl)-2,3-dihydro-1H-indol-6-yl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{4-Methoxy-3-[2-(2-morpholin-4-yl-ethylamino)-ethoxy]-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-[4-Methoxy-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-(4-Methoxy-3-{2-[(pyridin-2-ylmethyl)-amino]-ethoxy}-phenyl)-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{4-Methoxy-3-[2-(tetrahydro-pyran-4-ylamino)-ethoxy]-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{4-Methoxy-3-[2-(1-methyl-piperidin-4-ylamino)-ethoxy]-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{3-[2-Hydroxy-3-(tetrahydro-pyran-4-ylamino)-propoxy]-4-methoxy-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{3-[2-Hydroxy-3-(pyridin-4-ylamino)-propoxy]-4-methoxy-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{3-[2-Hydroxy-3-(1-methyl-piperidin-4-ylamino)-propoxy]-4-methoxy-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
-
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-morpholin-4-yl-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(dimethyl-morpholin-4-yl)-acetamide trifluoroacetate
- 2-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2,2,2-trifluoro-ethylamino)-acetamide trifluoroacetate
- 2-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-thiomorpholin-4-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-pyrrolidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-piperazin-1-yl)-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-piperidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-2-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-3-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-4-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-hydroxy-ethylamino)-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-methoxy-ethylamino)-acetamide trifluoroacetate
- 2-Dimethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- 2-(Cyanomethyl-amino)-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-[1,4]diazepan-1-yl)-acetamide trifluoroacetate
- 2-tert-Butylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(1,2,2-trimethyl-propylamino)-acetamide trifluoroacetate
- ({[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-amino)-acetic acid methyl ester; compound with trifluoro-acetic acid
- 2-(2,2-Difluoro-ethylamino)-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide; compound with trifluoro-acetic acid
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4,4-dimethyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-trifluoromethyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[1,4]oxazepan-4-yl-acetamide
- 1-{[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-pyrrolidine-3-carboxylic acid methyl ester
- 2-Azetidin-1-yl-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-fluoro-ethylamino)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(2-methoxy-ethyl)-methyl-amino]-acetamide
- ({[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-amino)-acetic acid trifluoroacetate
- 2-Cyclohexylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- 2-Cyclopropylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-morpholin-4-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(dimethyl-morpholin-4-yl)-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(4-methyl-piperazin-1-yl)-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-piperidin-1-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-thiomorpholin-4-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-pyrrolidin-1-yl-propionamide trifluoroacetate
- 3-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(2,2,2-trifluoro-ethylamino)-propionamide; compound with trifluoro-acetic acid
- 3-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-morpholin-4-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-piperidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-(4-methyl-piperazin-1-yl)-acetamide trifluoroacetate
- 2-Dimethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-tert-Butylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 1-Methyl-piperidine-4-carboxylic acid [5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-amide, trifluoro-acetate
- 3-[3-(2-Cyclopentylamino-ethoxy)-4-methoxy-phenyl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-(3-{2-[(Furan-2-ylmethyl)-amino]-ethoxy}-4-methoxy-phenyl)-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{3-[2-(2-Hydroxy-1-phenyl-ethylamino)-ethoxy]-4-methoxy-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-[3,3-Dimethyl-1-(2-morpholin-4-yl-acetyl)-2,3-dihydro-1H-indol-6-yl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-[3,3-Dimethyl-1-(2-thiomorpholin-4-yl-acetyl)-2,3-dihydro-1H-indol-6-yl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
(Scheme 7) The intermediates 7c formed are then converted into compounds of general formula I by alkylation with a halide Hal-L2-Y-R5 or another reagent of similar reactivity. The alkylation reactions are preferably performed in an organic solvent, for instance dimethylformamide, N-methylpyrrolidone, ethyl acetate or acetone, in the presence of a base, for instance potassium carbonate, caesium carbonate, sodium hydride or potassium tert-butoxide. The bases dimethylformamide and caesium carbonate are preferably used.
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-morpholin-4-yl-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(dimethyl-morpholin-4-yl)-acetamide trifluoroacetate
- 2-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2,2,2-trifluoro-ethylamino)-acetamide trifluoroacetate
- 2-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-thiomorpholin-4-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-pyrrolidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-piperazin-1-yl)-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-piperidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-2-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-3-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-4-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-hydroxy-ethylamino)-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-methoxy-ethylamino)-acetamide trifluoroacetate
- 2-Dimethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- 2-(Cyanomethyl-amino)-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-[1,4]diazepan-1-yl)-acetamide trifluoroacetate
- 2-tert-Butylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(1,2,2-trimethyl-propylamino)-acetamide trifluoroacetate
- ({[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-amino)-acetic acid methyl ester; compound with trifluoro-acetic acid
- 2-(2,2-Difluoro-ethylamino)-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide; compound with trifluoro-acetic acid
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4,4-dimethyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-trifluoromethyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[1,4]oxazepan-4-yl-acetamide
- 1-{[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-pyrrolidine-3-carboxylic acid methyl ester
- 2-Azetidin-1-yl-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-fluoro-ethylamino)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(2-methoxy-ethyl)-methyl-amino]-acetamide
- ({[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-amino)-acetic acid trifluoroacetate
- 2-Cyclohexylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- 2-Cyclopropylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-morpholin-4-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(dimethyl-morpholin-4-yl)-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(4-methyl-piperazin-1-yl)-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-piperidin-1-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-thiomorpholin-4-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-pyrrolidin-1-yl-propionamide trifluoroacetate
- 3-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(2,2,2-trifluoro-ethylamino)-propionamide; compound with trifluoro-acetic acid
- 3-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-morpholin-4-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-piperidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-(4-methyl-piperazin-1-yl)-acetamide trifluoroacetate
- 2-Dimethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-tert-Butylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 1-Methyl-piperidine-4-carboxylic acid [5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-amide, trifluoro-acetate
- 3-[3-(2-Cyclopentylamino-ethoxy)-4-methoxy-phenyl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-(3-{2-[(Furan-2-ylmethyl)-amino]-ethoxy}-4-methoxy-phenyl)-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{3-[2-(2-Hydroxy-1-phenyl-ethylamino)-ethoxy]-4-methoxy-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-[3,3-Dimethyl-1-(2-morpholin-4-yl-acetyl)-2,3-dihydro-1H-indol-6-yl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-[3,3-Dimethyl-1-(2-thiomorpholin-4-yl-acetyl)-2,3-dihydro-1H-indol-6-yl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{4-Methoxy-3-[2-(2-morpholin-4-yl-ethylamino)-ethoxy]-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-[4-Methoxy-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-(4-Methoxy-3-{2-[(pyridin-2-ylmethyl)-amino]-ethoxy}-phenyl)-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{4-Methoxy-3-[2-(tetrahydro-pyran-4-ylamino)-ethoxy]-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{4-Methoxy-3-[2-(1-methyl-piperidin-4-ylamino)-ethoxy]-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{3-[2-Hydroxy-3-(tetrahydro-pyran-4-ylamino)-propoxy]-4-methoxy-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{3-[2-Hydroxy-3-(pyridin-4-ylamino)-propoxy]-4-methoxy-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{3-[2-Hydroxy-3-(1-methyl-piperidin-4-ylamino)-propoxy]-4-methoxy-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-morpholin-4-yl-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(dimethyl-morpholin-4-yl)-acetamide trifluoroacetate
- 2-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2,2,2-trifluoro-ethylamino)-acetamide trifluoroacetate
- 2-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-thiomorpholin-4-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-pyrrolidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-piperazin-1-yl)-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-piperidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-2-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-3-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(pyridin-4-ylmethyl)-amino]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-hydroxy-ethylamino)-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-methoxy-ethylamino)-acetamide trifluoroacetate
- 2-Dimethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- 2-(Cyanomethyl-amino)-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-methyl-[1,4]diazepan-1-yl)-acetamide trifluoroacetate
- 2-tert-Butylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(1,2,2-trimethyl-propylamino)-acetamide trifluoroacetate
- ({[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-amino)-acetic acid methyl ester; compound with trifluoro-acetic acid
- 2-(2,2-Difluoro-ethylamino)-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide; compound with trifluoro-acetic acid
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4,4-dimethyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(4-trifluoromethyl-piperidin-1-yl)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[1,4]oxazepan-4-yl-acetamide
- 1-{[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-pyrrolidine-3-carboxylic acid methyl ester
- 2-Azetidin-1-yl-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-(2-fluoro-ethylamino)-acetamide
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-2-[(2-methoxy-ethyl)-methyl-amino]-acetamide
- ({[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenylcarbamoyl]-methyl}-amino)-acetic acid trifluoroacetate
- 2-Cyclohexylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- 2-Cyclopropylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-morpholin-4-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(dimethyl-morpholin-4-yl)-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(4-methyl-piperazin-1-yl)-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-piperidin-1-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-thiomorpholin-4-yl-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-pyrrolidin-1-yl-propionamide trifluoroacetate
- 3-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-3-(2,2,2-trifluoro-ethylamino)-propionamide; compound with trifluoro-acetic acid
- 3-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-propionamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-morpholin-4-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-piperidin-1-yl-acetamide trifluoroacetate
- N-[5-(4,4-Dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-2-(4-methyl-piperazin-1-yl)-acetamide trifluoroacetate
- 2-Dimethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-Diethylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-tert-Butylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 2-Cyclopentylamino-N-[5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-isopropyl-phenyl]-acetamide trifluoroacetate
- 1-Methyl-piperidine-4-carboxylic acid [5-(4,4-dimethyl-2,5-dioxo-3-pyridin-4-ylmethyl-imidazolidin-1-yl)-2-trifluoromethoxy-phenyl]-amide, trifluoro-acetate
- 3-[3-(2-Cyclopentylamino-ethoxy)-4-methoxy-phenyl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-(3-{2-[(Furan-2-ylmethyl)-amino]-ethoxy}-4-methoxy-phenyl)-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-{3-[2-(2-Hydroxy-1-phenyl-ethylamino)-ethoxy]-4-methoxy-phenyl}-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-[3,3-Dimethyl-1-(2-morpholin-4-yl-acetyl)-2,3-dihydro-1H-indol-6-yl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
- 3-[3,3-Dimethyl-1-(2-thiomorpholin-4-yl-acetyl)-2,3-dihydro-1H-indol-6-yl]-5,5-dimethyl-1-quinolin-4-ylmethyl-imidazolidine-2,4-dione
Product of Example 9 | 0.2 | g | ||
Excipient for a finished tablet weighing | 1 | g | ||
(details of the excipient: lactose, talc, starch, | ||||
magnesium stearate). | ||||
Product of Example 32 | 0.2 | g | ||
Excipient for a finished tablet weighing | 1 | g | ||
(details of the excipient: lactose, talc, starch, | ||||
magnesium stearate). | ||||
Claims (18)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04291904 | 2004-07-27 | ||
EP04291904.3 | 2004-07-27 | ||
EP04291904A EP1621536A1 (en) | 2004-07-27 | 2004-07-27 | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
PCT/EP2005/008720 WO2006010641A2 (en) | 2004-07-27 | 2005-07-25 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/008720 Continuation WO2006010641A2 (en) | 2004-07-27 | 2005-07-25 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080004300A1 US20080004300A1 (en) | 2008-01-03 |
US7759379B2 true US7759379B2 (en) | 2010-07-20 |
Family
ID=34931289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/627,518 Expired - Fee Related US7759379B2 (en) | 2004-07-27 | 2007-01-26 | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
Country Status (20)
Country | Link |
---|---|
US (1) | US7759379B2 (en) |
EP (2) | EP1621536A1 (en) |
JP (1) | JP2008508228A (en) |
KR (1) | KR20070038529A (en) |
CN (1) | CN101031559A (en) |
AR (1) | AR050269A1 (en) |
AT (1) | ATE498618T1 (en) |
AU (1) | AU2005266460A1 (en) |
BR (1) | BRPI0512681A (en) |
CA (1) | CA2571323A1 (en) |
DE (1) | DE602005026395D1 (en) |
EA (1) | EA011088B1 (en) |
IL (1) | IL180286A0 (en) |
MA (1) | MA28732B1 (en) |
MX (1) | MX2007001024A (en) |
NO (1) | NO20071067L (en) |
PE (1) | PE20060383A1 (en) |
TW (1) | TW200616973A (en) |
UY (1) | UY29039A1 (en) |
WO (1) | WO2006010641A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080021029A1 (en) * | 2004-07-27 | 2008-01-24 | Aventis Pharma S.A. | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7354933B2 (en) * | 2003-01-31 | 2008-04-08 | Aventis Pharma Sa | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
EP1621539A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
FR2896504B1 (en) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
FR2896503B1 (en) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | NOVEL CYCLIC UREA SULFUR DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
PT2656842T (en) | 2006-03-27 | 2016-10-04 | Univ California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
US8835426B2 (en) * | 2007-02-26 | 2014-09-16 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
ES2395081T3 (en) * | 2007-07-26 | 2013-02-08 | Vitae Pharmaceuticals, Inc. | Synthesis of 11 beta-hydroxysteroid dehydrogenase inhibitors type 1 |
AR069207A1 (en) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | CYCLIC UREAS AS INHIBITORS OF THE 11 BETA - HIDROXI-ESTEROIDE DESHIDROGENASA 1 |
US8440658B2 (en) | 2007-12-11 | 2013-05-14 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
WO2009094169A1 (en) * | 2008-01-24 | 2009-07-30 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5734666B2 (en) * | 2008-02-11 | 2015-06-17 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 1,3-oxaazepan-2-one and 1,3-diazepan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
US8598160B2 (en) * | 2008-02-15 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
EP2274287B1 (en) * | 2008-03-18 | 2016-03-09 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
JP5451752B2 (en) * | 2008-05-01 | 2014-03-26 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1 |
EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
AR071609A1 (en) * | 2008-05-01 | 2010-06-30 | Vitae Pharmaceuticals Inc | CYCLICAL INHIBITORS OF 11 (BETA) -HYDROXIESTEROID DEHYDROGENASE 1 |
CA2723039A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8846668B2 (en) | 2008-07-25 | 2014-09-30 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5379160B2 (en) | 2008-07-25 | 2013-12-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1 |
WO2010089303A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1 |
TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
GEP20156309B (en) * | 2009-04-30 | 2015-07-10 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
UA109255C2 (en) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8927539B2 (en) | 2009-06-11 | 2015-01-06 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure |
US8883778B2 (en) | 2009-07-01 | 2014-11-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
CN102639700A (en) | 2009-09-30 | 2012-08-15 | 哈佛大学校长及研究员协会 | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
WO2011159760A1 (en) | 2010-06-16 | 2011-12-22 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
EP2585444B1 (en) | 2010-06-25 | 2014-10-22 | Boehringer Ingelheim International GmbH | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
JP2013540801A (en) | 2010-11-02 | 2013-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination medicine for the treatment of metabolic disorders |
UA124967C2 (en) | 2012-09-26 | 2021-12-22 | Араґон Фармасьютікалз, Інк. | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER |
RU2712233C2 (en) * | 2014-09-29 | 2020-01-27 | Кемосентрикс, Инк. | METHODS AND INTERMEDIATES IN PRODUCING C5aR ANTAGONISTS |
AU2019387367A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
WO2021057696A1 (en) * | 2019-09-27 | 2021-04-01 | 隆泰申医药科技(南京)有限公司 | Heteroaryl compound and application thereof |
CN114591335B (en) * | 2021-03-29 | 2023-06-27 | 浙江大学 | Indazole compound, preparation method and application thereof |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0034536A2 (en) | 1980-02-18 | 1981-08-26 | Roussel-Uclaf | Oxime derivatives of 3-alkyloxy- or 3-alkylthiomethyl 7-amino-thiazolylacetamido cephalosporanic acid, their preparation, their use as medicaments and compositions containing them |
EP0494819A1 (en) | 1991-01-09 | 1992-07-15 | Roussel Uclaf | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them |
US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
US6004963A (en) | 1995-10-27 | 1999-12-21 | Gruenenthal Gmbh | Substituted 2, 4-imidazolidinedione compounds as pharmaceutical active ingredients |
US6022875A (en) | 1997-07-31 | 2000-02-08 | Gruenenthal Gmbh | Use of substituted 2,4-imidazolidinedione compounds as analgesics |
US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
WO2001009090A2 (en) | 1999-07-30 | 2001-02-08 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines |
WO2004022572A1 (en) | 2002-09-06 | 2004-03-18 | Alchemia Limited | Compounds that interact with kinases |
WO2004070050A2 (en) | 2003-01-31 | 2004-08-19 | Aventis Pharma S.A. | Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
US20040248884A1 (en) | 2003-01-31 | 2004-12-09 | Aventis Pharma S.A. | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
WO2005049580A1 (en) | 2003-11-13 | 2005-06-02 | Bristol-Myers Squibb Company | Monocyclic n-aryl hydantoin modulators of androgen receptor function |
WO2006010643A1 (en) | 2004-07-27 | 2006-02-02 | Aventis Pharma S.A. | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
WO2006010642A1 (en) | 2004-07-27 | 2006-02-02 | Aventis Pharma S.A. | Heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
-
2004
- 2004-07-27 EP EP04291904A patent/EP1621536A1/en not_active Withdrawn
-
2005
- 2005-07-25 BR BRPI0512681-9A patent/BRPI0512681A/en not_active IP Right Cessation
- 2005-07-25 KR KR1020077002102A patent/KR20070038529A/en not_active Application Discontinuation
- 2005-07-25 AT AT05771072T patent/ATE498618T1/en not_active IP Right Cessation
- 2005-07-25 EA EA200700141A patent/EA011088B1/en not_active IP Right Cessation
- 2005-07-25 AU AU2005266460A patent/AU2005266460A1/en not_active Abandoned
- 2005-07-25 JP JP2007523038A patent/JP2008508228A/en active Pending
- 2005-07-25 DE DE602005026395T patent/DE602005026395D1/en active Active
- 2005-07-25 WO PCT/EP2005/008720 patent/WO2006010641A2/en active Application Filing
- 2005-07-25 AR ARP050103075A patent/AR050269A1/en unknown
- 2005-07-25 EP EP05771072A patent/EP1773808B1/en active Active
- 2005-07-25 MX MX2007001024A patent/MX2007001024A/en not_active Application Discontinuation
- 2005-07-25 CA CA002571323A patent/CA2571323A1/en not_active Abandoned
- 2005-07-25 PE PE2005000866A patent/PE20060383A1/en not_active Application Discontinuation
- 2005-07-25 CN CNA2005800250805A patent/CN101031559A/en active Pending
- 2005-07-26 TW TW094125192A patent/TW200616973A/en unknown
- 2005-07-27 UY UY29039A patent/UY29039A1/en unknown
-
2006
- 2006-12-24 IL IL180286A patent/IL180286A0/en unknown
-
2007
- 2007-01-02 MA MA29602A patent/MA28732B1/en unknown
- 2007-01-26 US US11/627,518 patent/US7759379B2/en not_active Expired - Fee Related
- 2007-02-26 NO NO20071067A patent/NO20071067L/en not_active Application Discontinuation
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4992431A (en) | 1980-02-18 | 1991-02-12 | Rousseluclaf | Cephalosporins |
EP0034536A2 (en) | 1980-02-18 | 1981-08-26 | Roussel-Uclaf | Oxime derivatives of 3-alkyloxy- or 3-alkylthiomethyl 7-amino-thiazolylacetamido cephalosporanic acid, their preparation, their use as medicaments and compositions containing them |
EP0494819A1 (en) | 1991-01-09 | 1992-07-15 | Roussel Uclaf | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them |
US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
US6004963A (en) | 1995-10-27 | 1999-12-21 | Gruenenthal Gmbh | Substituted 2, 4-imidazolidinedione compounds as pharmaceutical active ingredients |
US6022875A (en) | 1997-07-31 | 2000-02-08 | Gruenenthal Gmbh | Use of substituted 2,4-imidazolidinedione compounds as analgesics |
US6759415B1 (en) | 1999-07-30 | 2004-07-06 | Societe De Conseils De Recherches Et D' Applications Scientifiques | Hydantoin thiohydantoin pyrimidinedione and thioxopyrimidinone derivatives preparation method and use as medicines |
WO2001009090A2 (en) | 1999-07-30 | 2001-02-08 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines |
US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
WO2004022572A1 (en) | 2002-09-06 | 2004-03-18 | Alchemia Limited | Compounds that interact with kinases |
WO2004070050A2 (en) | 2003-01-31 | 2004-08-19 | Aventis Pharma S.A. | Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
US20040248884A1 (en) | 2003-01-31 | 2004-12-09 | Aventis Pharma S.A. | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
US20080108654A1 (en) | 2003-01-31 | 2008-05-08 | Aventis Pharma S.A. | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors |
WO2005049580A1 (en) | 2003-11-13 | 2005-06-02 | Bristol-Myers Squibb Company | Monocyclic n-aryl hydantoin modulators of androgen receptor function |
WO2006010643A1 (en) | 2004-07-27 | 2006-02-02 | Aventis Pharma S.A. | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
WO2006010642A1 (en) | 2004-07-27 | 2006-02-02 | Aventis Pharma S.A. | Heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
Non-Patent Citations (35)
Title |
---|
Baserga, The IGF-I Receptor in Cancer Research, Exp. Cell. Res., 1999 (253) pp. 1-6. |
Bundgaard et al, A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group, J. Med. Chem., 1989 (32) 12, pp. 2503-2507. |
Cardone et al, Regulation of Cell Death Protease Caspase-9 by Phosphorylation, Science, 1998 (282) pp. 1318-1321. |
Cary et al, Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn, Journal of Cell Science, 1996 (109), pp. 1787-1794. |
Chan et. al., The Role of Protein Tyrosine Kinases and Protein Tyrosine Phosphatases in T Cell Antigen Receptor Signal Transduction, Annu. Rev. Immunol., 1994 (12), pp. 555-592. |
Chen et al, Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase, Proc. Natl. Acad. Sci. USA, 1994 (91), pp. 10148-10152. |
Dyer et al, Preparation of Poly(hydrouracils) and Poly(iminoimidazolidinones), Journal of Polymer Science, Polymer Chemistry Edition, 1969, 7(3), pp. 833-849. |
Hanks et al, The Eukaryotic Protein Kinase Superfamily: Kinase (Catalytic) Domain Structure and Classification, FASEB, 1995 (9), pp. 576-596. |
Iwashita et al, Signal Transduction System for Growth Factor Receptors Associated with Tyrosine Kinase Activity: Epidermal Growth Factor Receptor Signalling and its Regulation, Cellular Signalling, 1992 (4) 2, pp. 123-132. |
Khwaja, Akt is more than just a Bad kinase, Nature, 1999 (401), pp. 33-34. |
Kornberg et al, Cell Adhesion or Integrin Clustering Increases Phosphorylation of a Focal Adhesion-associated Tyrosine Kinase, J. Biol. Chem., 1992 (267) 33, pp. 23439-23442. |
Ling et al, Malignant Astrocytoma Cell Attachment and Migration to Various Matrix Proteins Is Differentially Sensitive to Phosphoinositide 3-OH Kinase Inhibitors, J. Cell. Biochemistry, 1999 (73), pp. 533-544. |
Maung et al, Requirement for focal adhesion kinase in tumor cell adhesion, Oncogene,1999 (18), pp. 6824-6828. |
Mazure et al, Induction of Vascular Endothelial Growth Factor by Hypoxia Is Modulated by a Phosphatidylinositol 3-Kinase/Akt Signaling Pathway in Ha-ras-Transformed Cells Through a Hypoxia Inducible Factor-1 Transcriptional Element, Blood, 1997 (90) 9, pp. 3322-3331. |
Newton et al, Protein Kinase C: Structure, Function, and Regulation, J. Biol. Chem., 1995 (270) 48, pp. 28495-28498. |
Oktay et al, Integrin-mediated Activation of Focal Adhesion Kinase Is Required for Signaling to Jun NH2-terminal Kinase and Progression through the G1 Phase of the Cell Cycle, J. Cell. Biol., 1999 (145) 7, pp. 1461-1469. |
Owens et al, Overexpression of the Focal Adhesion Kinase (p125 FAK) in Invasive Human Tumors 1, Cancer Research, 1995 (55), pp. 2752-2755. |
Pines, Cyclins and cyclin-dependent kinases: take your partners, Trends in Biochemical Sciences, 1993 (18), pp. 195-197. |
Richardson et al, A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125 FAK, Nature, 1996 (380), pp. 538-540. |
Schaller et al, Autophosphorylation of the Focal Adhesion Kinase, pp125 FAK, Directs SH2-Dependent Binding of pp60src, Mol. Cell. Biol., 1994 (14), pp. 1680-1688. |
Schlaepfer et al, Focal Adhesion Kinase Overexpression Enhances Ras-dependent Integrin Signaling to ERK2/Mitogen-activated Protein Kinase through Interactions with and Activation of c-Src, J. Biol. Chem., 1997 (272) 20, pp. 13189-13195. |
Schlaepfer et al, Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase, Nature, 1994 (372) 22, pp. 786-791. |
Schlaepfer et al, Signaling through focal adhesion kinase, Prog. Biophy. Mol. Biol., 1999 (71), pp. 435-478. |
Sieg et al, Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration, J. Cell Science, 1999 (112), pp. 2677-2691. |
U.S. Appl. No. 11/627,505, filed Jan. 26, 2007, Strobel et al. |
U.S. Appl. No. 11/627,515, filed Jan. 26, 2007, Strobel et al. |
U.S. Appl. No. 12/173,191, filed Jul. 15, 2008, Halley et al. |
U.S. Appl. No. 12/173,380, filed Jul. 15, 2008, Halley et al. |
Vuori et al, Induction of p130cas Signaling Complex Formation upon Integrin-Mediated Cell Adhesion: a Role for Src Family Kinases, Mol. Cell. Biol., 1996 (16) 6, pp. 2606-2613. |
Wang et al, p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo, J. Cell Sci., 2000 (113), pp. 4221-4230. |
Weiner et al, Expression of focal adhesion kinase gene and Invasive cancer, Lancet., 1993 (342), pp. 1024-1025. |
Xing et al, Direct Interaction of v-Src with the Focal Adhesion Kinase Mediated by the Src SH2 Domain, Mol. Cell. Biol., 1994 (5), pp. 413-421. |
Xu et al, Attenuation of the Expression of the Focal Adhesion Kinase Induces Apoptosis in Tumor Cells, Cell Growth Diff., 1996 (7), pp. 413-418. |
Zhao et al, Regulation of the Cell Cycle by Focal Adhesion Kinase, J. Cell. Biol., 1998 (143) 7, pp. 1997-2008. |
Zhong et al, Modulation of Hypoxia-inducible Factor 1 alpha Expression by the Epidermal Growth Factor/Phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP Pathway in Human Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics, Cancer Research, 2000 (60), pp. 1541-1545. |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080021029A1 (en) * | 2004-07-27 | 2008-01-24 | Aventis Pharma S.A. | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors |
Also Published As
Publication number | Publication date |
---|---|
KR20070038529A (en) | 2007-04-10 |
EA011088B1 (en) | 2008-12-30 |
NO20071067L (en) | 2007-04-26 |
WO2006010641A3 (en) | 2006-10-26 |
JP2008508228A (en) | 2008-03-21 |
TW200616973A (en) | 2006-06-01 |
MX2007001024A (en) | 2007-04-16 |
UY29039A1 (en) | 2006-02-24 |
EA200700141A1 (en) | 2007-08-31 |
BRPI0512681A (en) | 2008-04-01 |
AU2005266460A1 (en) | 2006-02-02 |
DE602005026395D1 (en) | 2011-03-31 |
PE20060383A1 (en) | 2006-06-06 |
IL180286A0 (en) | 2007-07-04 |
CA2571323A1 (en) | 2006-01-02 |
WO2006010641A2 (en) | 2006-02-02 |
EP1773808A2 (en) | 2007-04-18 |
ATE498618T1 (en) | 2011-03-15 |
CN101031559A (en) | 2007-09-05 |
AR050269A1 (en) | 2006-10-11 |
MA28732B1 (en) | 2007-07-02 |
US20080004300A1 (en) | 2008-01-03 |
EP1773808B1 (en) | 2011-02-16 |
EP1621536A1 (en) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7759379B2 (en) | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
US20080021029A1 (en) | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | |
EP1599464B1 (en) | Novel cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors | |
US20070259891A1 (en) | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | |
US7625889B2 (en) | Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists | |
US7935819B2 (en) | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
US7825115B2 (en) | Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
US20090082329A1 (en) | Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | |
EP1989196B1 (en) | Piperidinoylpyrrolidines as melanocortin type 4 receptor agonists | |
HRP970371A2 (en) | Heterocyclic compounds | |
IL178287A (en) | Imidazole compounds and pharmaceutical compositions comprising them | |
JP2009503050A (en) | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds | |
US7442693B2 (en) | Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors | |
US20230026909A1 (en) | 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors | |
WO2017108736A1 (en) | N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors | |
RU2797613C2 (en) | 1,2,4-oxadiazole derivatives as histonedeacetilase 6 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STROBEL, HARTMUT;RUF, SVEN;GUESSREGEN, STEFAN;AND OTHERS;REEL/FRAME:019642/0572 Effective date: 20070420 |
|
AS | Assignment |
Owner name: AVENTIS PHARMA S.A., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SANOFI-AVENTIS DEUTSCHLAND GMBH;REEL/FRAME:019682/0955 Effective date: 20070420 |
|
AS | Assignment |
Owner name: AVENTIS PHARMA S.A.., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LESUISSE, DOMINIQUE;NEMECEK, CONCEPTION;EL-AHMAD, YOUSSEF;AND OTHERS;REEL/FRAME:019905/0164;SIGNING DATES FROM 20070503 TO 20070521 Owner name: AVENTIS PHARMA S.A.., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LESUISSE, DOMINIQUE;NEMECEK, CONCEPTION;EL-AHMAD, YOUSSEF;AND OTHERS;SIGNING DATES FROM 20070503 TO 20070521;REEL/FRAME:019905/0164 |
|
AS | Assignment |
Owner name: AVENTIS PHARMA S.A., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SANOFI-AVENTIS DEUTSCHLAND GMBH;REEL/FRAME:019918/0791 Effective date: 20070420 |
|
CC | Certificate of correction | ||
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20140720 |